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Dedication ((optional)) 
The Suzuki-Miyaura derivatisation of free amino acids, peptides 
and proteins is an attractive area with much potential utility for 
medicinal chemistry and chemical biology. Here we report the 
modification of unprotected and Boc-protected aromatic amino 
acids and dipeptides in aqueous media, enabling 
heteroarylation and vinylation. We systematically investigate 
the impact of the peptide backbone and adjacent amino acid 
residues upon the reaction. Our studies reveal that whilst 
asparagine and histidine hinder the reaction, by utilising dppf, a 
ferrocene-based bidentate phosphine ligand, cross-coupling of 
halophenylalanine or halotryptophan adjacent to such a residue 
could be enabled. Our studies reveal dppf to have good 
compatibility with all unprotected, proteinogenic amino acid 
side chains.  
Introduction 
Since the discovery of palladium’s catalytic potential, numerous 
reactions have been developed for the formation of carbon-
carbon and carbon-heteroatom bonds.[1] Through the 
development of the Suzuki-Miyaura reaction, organoboron 
compounds were introduced as versatile coupling partners.[2] 
The use of boron as an organometallic partner provides several 
advantages such as its environmentally benign nature, 
commercial availability, high functional group tolerance and a 
compatibility with aqueous conditions.[3] The Suzuki-Miyaura 
reaction is therefore often the method of choice for the 
derivatisation of challenging substrates. It has been utilised for 
the derivatisation of biomolecules such as nucleosides,[4] amino 
acids,[5] peptides,[6] but also more complex natural products,[7] 
and proteins.[5c-d, 8] Site-selective derivatisation of peptides and 
proteins by bioorthogonal reactions[9] has received great 
attention as a key component of the chemical biology toolbox 
and for the labeling of bioactive products.[8c-d, 10] Additionally, one 
can explore structure-activity relationships for these biological 
substrates via the synthesis of related structures, enabled by the 
presence of a “derivatisation handle” in the amino acid sequence.  
Introducing halogens onto the side chains of phenylalanine 
and tryptophan,[11] for example, opens opportunities for late-
stage peptide functionalisation via palladium-catalysed cross-
coupling reactions. Ideally, performing these derivatisations in a 
late stage of the synthetic pathway would provide a convergent 
method for rapid screening of structurally related compounds. 
However, when (partially) unprotected peptide substrates have 
to be derivatised, the envisaged Pd-catalysed reactions require 
aqueous conditions to mimic the natural environment of these 
biomolecules. To find catalytic systems that are compatible with 
water, various alterations to commonly used reaction conditions 
in organic solvents have been reported.[12] Unfortunately, when 
aiming at more complex substrates, (super)stoichiometric 
amounts of catalyst and ligand are often required.[5d,13] Clearly, 
catalytic amounts are preferred in view of the associated price of 
the Pd source and ligand used and in order to avoid large 
amounts of residual Pd to be scavenged after the reaction.[14] 
Herein, to address this issue, a compatibility study between 
Suzuki-Miyaura derivatisation and amino acid main and side 
chain functionalities was carried out via a systematic screening. 
By synthesis of dipeptide substrates containing a halogenated 
phenylalanine, the compatibility of various side chain 
functionalities could be screened. In this way, each side chain 
can be investigated individually, ultimately leading to a tool to 
make predictions for more complex substrates, i.e. polypeptides. 
Results and Discussion 
Evaluation of various Pd/Ligand systems on 4-
bromophenylalanine as a model substrate 
To achieve the required compatibility with aqueous conditions, 
an adaptation of the catalytic species is mandatory. Several 
examples of water soluble ligands have been reported. We 
screened complexes of 2-aminopyrimidine-4,6-diol disodium 
salt (Na2ADHP, 1a)
[5d, 15], 2-(dimethylamino)pyrimidine-4,6-diol 
disodium salt (Na2ADHP(Me2), 1b)
[8d, 14a], 3,3′,3″-
phosphanetriyltris(benzene sulfonic acid) trisodium salt (TPPTS, 
2)[4e, 5a], and sodium 2-dicyclohexylphosphino-2',6'-
dimethoxybiphenyl-3’-sulfonate (sulfonated SPhos, 3)[3c, 7a]. 
Beside precatalysts based on these ligands, we also evaluated 
PdCl2dppf ([1,1′-bis(diphenylphosphino)ferrocene]palladium 
dichloride) (5a).[16a] This complex is considered to be insoluble 
in water, but has been used in aqueous media for the 
preparation of various biphenyls.[16b] Additionally, a 
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biphenylamino-based Pd precatalyst featuring this ligand (5b) 
was also tested[17] as well as ligandless Pd salts (4a,b).[8d, 18] 
 
Figure 1. Various palladium(-ligand) sources tested during the initial screening 
with 4-bromophenylalanine. 
A screening of these precatalysts was first performed on the 
model substrate 4-bromophenylalanine (6a) in a reaction with 
phenylboronic acid. Furthermore, in view of eventual SAR 
studies regioisomers, 3- (6b) and 2-bromophenylalanine (6c) 
were also evaluated in the Suzuki-Miyaura reactions with 
phenylboronic acid. 
 
Table 1. Preliminary screening with regioisomeric bromophenylalanines (6) as 
substrates in a cross-coupling reaction with phenylboronic acid. 
 
 
 
 
 
 
 
 
Entry Cat. Substrate Solvent Conv. /%
[a,b]
, Time /h 
1 1a 6a H2O 57% (2 h) - 90% (24 h) 
2 1b 6a H2O 99% (3 h) 
3 2 6a H2O 95% (4 h) 
4
[c]
 3 6a H2O 10% (2 h) - 42% (24 h) 
5 4a 6a H2O 53% (2 h) - 85% (24 h) 
6 4b 6a H2O 50% (2 h) - 87% (24 h) 
7 5a 6a H2O 2% (24 h) 
8 5a 6a aq. 5% iPrOH 80% (24 h) 
9 5a 6a aq. 50% iPrOH 99% (4 h) 
10 5b 6a aq. 50% iPrOH 78% (4 h) 
11 5a 6b aq. 50% iPrOH 49% (2 h) - 99% (4 h) 
12 5a 6c aq. 50% iPrOH 65% (4 h) 
[a] Reaction conditions: bromophenylalanine (6a-c) (0.1 mmol), 5 mol% 
catalyst (1-5), phenylboronic acid (1.2 eq), K2CO3 (5 eq), H2O or H2O/iPrOH (2 
mL), 80°C. [b] Measured by HPLC (215 nm, uncorrected). [c] Ratio ligand/Pd 
2.5:1. 
In pure water, the most promising results were obtained with 
precatalysts 1b (entry 2) and 2 (entry 3). While incomplete 
conversion to the desired product was observed with 5a in 
purely aqueous conditions (entry 7), changing to a mixed solvent 
system significantly improved the reaction outcome. Isopropanol 
(iPrOH) was selected as a green alternative[19] (entry 8 and 9) to 
more traditionally used organic solvents that are commonly 
applied in Suzuki-Miyaura transformations, such as toluene and 
DMF. No beneficial effect was found upon use of dppf based 
precatalyst 5b (entry 10). The 2-bromo regioisomer 6c (entry 12) 
required a longer reaction time to reach a high conversion, while 
the 3-bromo regioisomer 6b (entry 11) converted at an 
intermediate rate. These derivatisations are highly interesting 
since ortho- and meta halogenated regioisomers are generally 
not considered in the derivatisation of halophenylalanine 
substrates.[20] 
The use of 5a is, to the best of our knowledge, hitherto 
limited to the derivatisation of protected (4-
pinacolylborono)phenylalanine (BPA) with aromatic halides and 
triflates[16a] and has only been applied in aqueous conditions for 
the preparation of simple biphenyls.[16b] We therefore 
investigated the scope on unprotected and Boc-protected 
substrates, that can be directly applied in solid-phase peptide 
synthesis (SPPS). First, an optimisation of the iPrOH/water ratio 
was performed (Table 2). It was shown that for an unprotected 
substrate (6a), 50% iPrOH provided the highest conversion 
(entry 6) using 1 mol% of 5a. To achieve short cross-coupling 
reaction times (4 h), 5 mol% of 5a was required for complete 
conversion of 6a (entry 6 vs Table 1, entry 9). On the tert-
butyloxycarbonyl (Boc) protected substrate 8a, nearly complete 
conversion can be reached with as little as 1 mol% of 5a in a 
limited reaction time (2 h), while the amount of iPrOH required 
can be <5% (entry 2). As could be expected protected systems 
gave faster reaction but protection is interestingly not required. 
Avoiding these main chain protecting groups is a first step in the 
envisaged derivatisation of more complex peptide substrates in 
aqueous environment.   
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Table 2. iPrOH/H2O ratio optimisation for unprotected (6a) and Boc-protected 
4-bromophenylalanine (8a). 
 
 
 
 
 
 
 
 
Entry iPrOH /% Substrate Conv. /%
[a,b]
 Substrate Conv. /%
[a,b]
 
1 0% 6a 2 8a 94% 
2 5% 6a 32 8a 99% 
3 10% 6a 44 8a 99% 
4 25% 6a 58 8a 99% 
5 35% 6a 65 8a 99% 
6 50% 6a 74 8a 99% 
7 66% 6a 70 8a 99% 
8 80% 6a 45 8a 99% 
9 100% 6a 9 8a 71% 
[a] Reaction conditions: 4-bromophenylalanine (6a) (0.2 mmol) or Boc-4-
bromophenylalanine (8a) (0.15 mmol), 1 mol% 5a, phenylboronic acid (1.2 eq), 
K2CO3 (5 eq), % iPrOH in H2O (total 4 mL), 80°C. [b] Measured by HPLC (215 
nm, uncorrected).  
Boronic acid scope using the PdCl2(dppf) (5a) catalytic 
system 
Next the boronic acid scope was investigated with the optimised 
reaction conditions identified for reaction of 6a and 8a with 
phenylboronic acid using precatalyst 5a. Gratifyingly, various 
(hetero)aromatic boronic acids (Table 3, entry 1-7) can be 
introduced on the halogenated phenylalanine substrates 6a and 
8a, seemingly independent of the boronic acid. Although the 
reaction time was set at 2 hours during the initial solvent 
optimalisation experiments, complete conversion of 8a was 
reached after only 1 hour at 80°C. Purification of the N-terminally 
unprotected cross-coupled products (7a, d-j) was performed by 
preparative HPLC, delivering lower yields characteristic for 
HPLC purification. Higher isolated yields were obtained for all 
protected products (9a-h) due to an easier isolation with flash 
chromatography. Boc protected 4-bromophenylalanine generally 
reacted faster with boronic acids as was also observed in the 
model cross-coupling with phenylboronic acid (Table 2). Next, 9-
fluorenylmethyloxy-carbonyl protection (Fmoc) was also 
evaluated. On Fmoc-4-bromophenylalanine altered reaction 
conditions are required to avoid removal of the base-labile 
Fmoc-group observed at 80°C. Although, reaction at a lower 
temperature (40°C) under otherwise standard reaction 
conditions showed promising results, HPLC conversion only 
reached 80% after 24h (see supporting information). 
Entry Substrate Boronic acid 
Time 
/h 
Product 
Conv. /%
[a,b,c]
, 
Yield /% 
1 
6a 
8a 
 4 h 
1 h 
7a 
9a 
93% (48%)
[d] 
99% (83%)
 
2 
6a 
8a 
 4 h 
1 h 
7d 
9b 
99% (33%)
[d]
 
99% (88%) 
3 
6a 
8a 
 
4 h 
1 h 
7e 
9c 
79% (45%)
[d] 
99% (79%) 
4 
6a 
8a 
 
4 h 
1 h 
7f 
9d 
95% (60%)
[d] 
99% (85%) 
5 
6a 
8a 
 
4 h 
1 h  
7g 
9e 
98% (37%)
[d] 
99% (89%) 
6 
6a 
8a 
 4 h 
1 h 
7h 
9f 
94% (33%)
[d] 
99% (84%) 
7 
6a 
8a 
 4 h 
1 h 
7i 
9g 
97% (39%)
[d] 
99% (89%) 
8 8a 
 
24 h 9h 11%  
9 
10a 
11a 
 
2 h 
1 h 
7j 
9h 
95% (40%)
[d] 
99% (81%) 
10 11b 
 
1 h 9i 99% (89%) 
11 11c  1 h 9j 99% (89%) 
[a] Reaction conditions: R= H: halophenylalanine (6a, 10a) (0.1 mmol), 5 
mol% 5a, boronic acid (1.2 eq), K2CO3 (5 eq), aq. 50% iPrOH (2 mL), 4 h, 
80°C. [b] R= Boc: halophenylalanine (8a, 11a-c) amino acid halide (2 mmol), 1 
mol% 5a, boronic acid (1.2 eq), K2CO3 (5 eq), aq. 5% iPrOH (20 mL), 1 h, 
80°C. [c] Measured by HPLC (215 nm, uncorrected). [d] Isolated yields by 
preparative HPLC. 
In addition to (hetero)aromatic boronic acids, we investigated 
several non-aromatic boronic acids (Table 3). Whereas little 
success was obtained for aliphatic boronic acids, a vinylic 
substituent can be efficiently introduced, as exemplified by the 
use of potassium vinyltrifluoroborate as reagent. We opted for 
this trifluoroborate as a convenient alternative to vinyl boronic 
acid,[21a] which is reported to readily undergo polymerisation.[2h, 
21b] These potassium trifluoroborates can be used as bench-
stable alternatives to their respective boronic acids.[2c] During 
cross-coupling in aqueous conditions, these trifluoroborates 
hydrolyse readily to the corresponding boronic acid.[22] To 
Table 3. Suzuki-Miyaura reaction on unprotected (6a), Boc-protected 4-
bromophenylalanine (8a), unprotected (10a), and Boc-protected 4-
iodophenylalanine (11a-c). 
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achieve high conversions in an acceptable reaction time, 4-iodo-
phenylalanine (10a) needed to be employed as the substrate 
(Table 3, entry 8 vs 9). Interestingly, the vinyl group permits a 
broad scope of further derivatisations, potentially allowing to 
obtain a variety of hitherto unknown functionalised Phe 
analogues. In addition to the preparation of N-Boc-4-
vinylphenylalanine (9h), it was possible to perform the vinylation 
on the meta- and ortho-halogenated regioisomers (11b,c) as 
well, and with similar reactivities (entry 10 and 11). The 
preparation of protected vinylphenylalanine has primarily been 
described in organic solvents with vinylstannanes,[23] which 
suffer from several drawbacks such as poor atom-economy, 
toxicity and poor solubility in mixed aqueous conditions.[21a] To 
the best of our knowledge, this is the first reported vinylation 
reaction with trifluoroborates on (unprotected) halogenated 
aromatic amino acids that can be performed in mixed aqueous 
conditions. Only use of substituted alkenyl boronic acids has 
previously been reported by Davis and coworkers with 1a on a 
protected iodinated tyrosine and a protein complex.[5d] 
 
Evaluation of dipeptide substrates for Suzuki-Miyaura 
reactions 
In order to determine the applicability of the catalytic systems 
(Figure 1) on increasingly difficult substrates, an explorative 
study on a slightly more elaborate substrate, H-Gly-Phe(4-Br)-
OH (12a), was initially carried out (for experimental data, see 
supporting information). Similar to the results on halogenated 
phenylalanine substrates 6, precatalysts 1a, 1b and 2 gave 
desirable conversions (>95%, see supporting information) in a 
limited amount of time (2 h) in water with only 5 mol% of catalyst. 
However, in this case 2.5 equivalents of boronic acid were 
required to achieve high conversion. While 5a gave 
correspondingly high conversions in a mixed solvent (H2O/iPrOH 
1:1), the [Na2(ADHP)]2Pd(OAc)2 (1a) system was selected as a 
convenient catalyst to perform a scope study on dipeptides 12 
featuring side chain functionality (Table 4). Based on HPLC 
conversions we could determine combinations that inhibit or 
hamper cross-coupling.  
Entry Substrate Time /h Conv. /%/
[a,b]
 
1 H-Gly-Phe(4-Br)-OH (12a) 2 h >99% 
2 H-Ala-Phe(4-Br)-OH (12b) 2 h >99% 
3 H-Leu-Phe(4-Br)-OH (12c) 2 h >95% 
4 H-Ser-Phe(4-Br)-OH (12d) 2 h >99% 
5 H-Asp-Phe(4-Br)-OH (12e) 2 h >99% 
6
[c] H-Lys-Phe(4-Br)-OH (12f) 2 h >99% 
7 H-Phe-Phe(4-Br)-OH (12g) 6 h >99% 
8 H-Tyr-Phe(4-Br)-OH (12h) 6 h >95% 
9 H-Trp-Phe(4-Br)-OH (12i) 6 h >95% 
10 H-Asn-Phe(4-Br)-OH (12j) 24 h 0% 
11 H-Met-Phe(4-Br)-OH (12k) 2 h >99% 
12
[c]
 H-His-Phe(4-Br)-OH (12l) 24 h 0% 
13
[c]
 H-Arg-Phe(4-Br)-OH (12m) 2 h >99% 
[a] Reaction conditions: dipeptide bromide (12a-m) (0.063 mmol), 5 mol% 1a 
(0.01 M stock solution), phenylboronic acid (2.5 eq), K2CO3 (5 eq), H2O (2 mL), 
80°C. [b] Measured by HPLC (215 nm, uncorrected). [c] 6 eq instead of 5 eq. 
K2CO3. 
As can be seen in Table 4, most amino acid side chains 
(aliphatic, aromatic, acidic and basic) do not interfere and readily 
allow cross-coupling reaction. The thioether functionality of Met 
(12k) is remarkable in this respect as sulphur is known to poison 
Pd0.[5d, 24] However, for Asn (12j) and His (12l), containing a 
primary amide and imidazole moiety, respectively, no conversion 
was observed even after prolonged reaction times (Table 4, 
entry 10 and 12). A further evaluation of these substrates was 
performed by looking specifically at individual functionalities in 
the protected dipeptide substrates. 
 
Synthesis of derivatised dipeptides with asparagine (Asn) 
and histidine (His) 
To allow cross-coupling with 12j and 12l both dipeptides were 
prepared as their N- and C-terminal protected derivatives. First, 
Boc-Asn-Phe(4-Br)-OMe (14a) was investigated as a substrate 
and subjected to various reaction conditions (Table 5). We 
observed that only with PdCl2(dppf) (5a) a high conversion was 
obtained (Table 5, entry 6), although only the hydrolysed product 
17b was observed by HPLC analysis. Therefore the isolated 
yield could not be determined. In order to verify whether this 
smooth conversion could also be realised on partially 
deprotected dipeptides, a saponification was first carried out 
(Scheme 1). Since deprotection by hydrolysis in basic conditions 
led to aspartimide formation and resulted in a mixture of both the 
carboxylic acid (15) and primary amide side chain (14b), 
addition of formic acid (1.4 eq, 0.2 eq with respect to LiOH) was 
mandatory to avoid this side reaction.[25] 
 
 
 
 
 
 
Scheme 1. Aspartimide formation occurring during basic hydrolysis of 14a, 
giving rise to a mixture (85:15) of side chain amide (14b) and carboxylic acid. 
(15) via an aspartimide intermediate (16).  
 
Table 4. Suzuki-Miyaura reaction on 4-bromophenylalanine-containing 
dipeptide substrates (12) with [Na2ADHP]2Pd(OAc)2 (1a) as the precatalyst. 
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In fact, this aspartimide formation also occurred during the 
Suzuki-Miyaura derivatisation of 14b (Table 5, entry 7) and fully 
deprotected dipeptide 12j, yielding a 1:1 mixture of the 
carboxylic acid and primary amide in the side chain. Also here, a 
small amount of formic acid (0.2 eq with respect to K2CO3) 
solved the problem (entry 8 and 9).[25] This optimised procedure 
was then repeated with unprotected glutamine dipeptide 12n 
(entry 10), yielding H-Gln-Phe(4-phenyl)-OH 13n. As observed 
for amino acids, the lower isolated yields of the dipeptides can 
be explained by the necessity of purification by preparative 
HPLC.  
 
Entry Substrate Cat. 
Loading 
(mol%) 
Solvent 
Conv. (%)
[a,b] 
 
Yield (%) 
1 14a 1a 5 mol%  H2O No conv. 
2 14a 1b 5 mol% H2O No conv. 
3 14a 2 10 mol% H2O No conv. 
4 14a 1a 100 mol% H2O No conv. 
5 14a 4b 5 mol% H2O No conv. 
6
 14a 5a 5 mol%  aq. 50% iPrOH 99%
[c]
 
7 14b 5a 5 mol% aq. 50% iPrOH 99%
[d]
 
8
[e] 14b 5a 5 mol% aq. 50% iPrOH 95% (66%)
[f]
 
9
[e]
 12j 5a 5 mol% aq. 50% iPrOH 95% (32%)
[f]
 
10
[e]
 12n 5a 5 mol% aq. 50% iPrOH 83% (36%)
[f]
 
[a] Reaction conditions: Substrate (0.055 mmol, 14a,b, 12j,n), 5-100 mol% 
catalyst (0.01 M stock solution in case of 1a and 1b), phenylboronic acid (2.5 
eq), K2CO3 (5 eq), solvent (2 mL), 80°C, 2 h. [b] Measured by HPLC (215 nm, 
uncorrected). [c] 17b was formed instead of the expected methyl ester. [d] 
Side product (H-Asp-Phe(4-Ph)-OH, 13e) formed due to aspartimide formation 
(see scheme 1). [e] Reaction conditions as described in [a], with 1 eq of formic 
acid. [f] Isolation by preparative HPLC. 
In analogy to Asn, a stepwise deprotection was followed for 
histidine (Table 6). Dipeptide 18a, featuring a benzyloxymethyl 
(BOM) protection on the Nπ-position and methyl ester, was 
selected as BOM protecting allows selective N-Boc-removal by 
acidolysis. Similarly, whereas other catalytic systems fail to give 
conversion, PdCl2(dppf) (5a) provided high conversion in a 
limited time (Table 6, entry 4). A concomitant hydrolysis of the 
methyl ester was however also observed in this case, and 
therefore no isolated yield was determined. The Suzuki-Miyaura 
derivatisation of partially deprotected 18b (Table 6, entry 5) and 
18c (entry 6, unprotected main chain, imidazole protection was 
retained) was possible within 4h.  
 
Table 6. Evaluation of fully and partially protected His-Phe(4-X) dipeptides and 
tripeptides (18-19) in Suzuki-Miyaura reactions. 
 
 
 
 
 
 
 
 
 
 
 
 
Entry Substrate Cat. 
Loading 
(mol%) 
Solvent 
Conv. (%)
[a,b] 
Yield (%) 
1 18a 1a 5 mol%  H2O No conv. 
2 18a 2 10 mol% H2O No conv. 
3 18a 1a 100 mol% H2O No conv. 
4 18a 5a 5 mol% aq.50% iPrOH 90%
[c]
 
5 18b 5a 5 mol% aq.50% iPrOH 95% (56%)
[c]
 
6
 18c 5a 5 mol%  aq.50% iPrOH 83% (42%)
[d]
 
7 19a 5a 5 mol% aq.50% iPrOH 25% (15%)
[d]
 
8
 19b 5a 5 mol% aq.50% iPrOH 50% (19%)
[d]
 
9 19c 5a 5 mol% aq.50% iPrOH 18% (11%)
[d]
 
10 19d 5a 5 mol% aq.50% iPrOH 50% (29%)
[d]
 
[a] Reaction conditions: Substrate (0.04 mmol, 18a-c or 0.02 mmol 19a-d), 5-
100 mol% catalyst (0.01 M stock solution in case of 1a and 1b), phenylboronic 
acid (2.5 eq), K2CO3 (5 eq), solvent (2 mL, or 1 mL for 19a-d), 80°C, 2-24 h. 
(standard 2 h, 4 h for 18c and 24 h for 19b,d. [b] Measured by HPLC (215 nm, 
uncorrected). [c] 20b was formed instead of the expected methyl ester. [d] 
Isolation by preparative HPLC. 
To avoid the need for a side chain protecting group on histidine, 
complexation of the imidazole with several metal halides was 
investigated (e.g. MgCl2, ZnCl2, NiCl2). After all, addition of 0.1 
equivalent of unprotected L-His to the successful reaction of 4-
bromophenylalanine and phenylboronic acid (Table 1, entry 9) 
nearly completely blocked the reaction pointing to catalyst 
inhibition through imidazole coordination (see supporting 
information). These metal halides are potentially capable of 
coordinating with the interfering functionality and make it less 
available for disrupting the desired catalysis on peptide 
substrates such as 12l.[13b, 26] Inhibition of typical Suzuki-Miyaura 
reactions by the presence of nitrogen-rich heterocycles, such as 
imidazole, has been reported in non-peptide systems.[27] 
Table 5. Evaluation of fully and partially protected Asn-Phe(4-Br) dipeptides 
(14) in Suzuki-Miyaura reactions. 
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Unfortunately, when sacrificial metals were present in the 
reaction mixture, no improvement was observed. Interestingly, 
significant amounts (up to 1 eq) of Boc-His-OMe could be added 
to the standard reaction (Table 1, entry 9) with retention of 
acceptable reaction progress (see supporting information). It 
therefore seems that it is the combination of an unprotected -
nitrogen and imidazole ring which blocks the catalysis.  
Subsequently, we turned towards the corresponding 
iodinated dipeptide substrate H-His-Phe(4-I)-OH (19a, Table 6, 
entry 7). Interestingly, upon use of this substrate it was possible 
to derivatise the fully deprotected dipeptide, albeit with a limited 
conversion and yield. To evaluate the effect of the free N-amine 
of His in combination with the imidazole moiety, the N-terminal 
amine was acetylated (19b). As expected, acylation of the N-
terminus led to higher conversion (Table 6, entry 8). A similar 
trend was observed for tripeptide H-Gly-His-Phe(4-I)-OH (19c) 
and the acylated equivalent (19d) (Table 6, entry 9-10). These 
results further indicated that an unprotected N-amine in 
combination with the unprotected imidazole of His is problematic 
for Suzuki-Miyaura reaction.  
To check whether this dipeptide moiety is also problematic in 
longer peptide sequences, an earlier reported His-containing 
heptapeptide 21[6a] was derivatised using PdCl2(dppf) (5a) 
precatalyst (Scheme 2). Via use of 5 mol% of 2, Barluenga and 
co-workers were able to achieve a HPLC conversion of 15-24% 
after 24 hours (depending on the boronic acid selected).[8a] 
Gratifyingly, using 5a this unprotected peptide was 
functionalised with 50% conversion after 2 hours to 22. 
Increased reaction times did, unfortunately, not further improve 
the conversion. This incomplete conversion is consistent with 
the results obtained for the unprotected His-Phe(4-I) containing 
dipeptides (19a,b) and tripeptides (19c,d) where no full 
conversion can be achieved (Table 6). This result shows that the 
imidazole moiety remains a troublesome functionality for 
palladium catalysed reactions, even upon elongation of the 
peptide substrates.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Derivatisation of heptapeptide 21, containing histidine and 4-
iodophenylalanine using 5a as precatalyst.  
 
In addition to side chain primary amides, we verified whether C-
terminal amides could also be used as substrates in the 
palladium-catalysed cross-coupling reactions (Table 7). With the 
classical catalyst systems (1a, 1b, 2 or 4a) we did not find any 
reaction product. This is all in line with the obtained results for 
Asn and Gln. However, by means of the ferrocene-based 
PdCl2(dppf) (5a), conversion of H-Ser-Phe(4-X)-NH2 (23a or 
24a) was only possible when the halogen moiety was iodine 
(entry 6). Excellent conversions were also observed with Leu, 
Tyr and Ala as the second amino acid component (entry 7-9). 
The brominated substrates (23a-d, entries 1-3) yielded side 
products only, whilst microwave heating did not improve the 
reaction outcome (entry 4 and 5).[28]  
Entry Substrate Conditions 
Conv. (%)
[a,b]
, 
 
Yield (%) 
1 H-Ser-Phe(4-Br)-NH2 (23a) 80°C, 24 h No conv. 
2 H-Leu-Phe(4-Br)-NH2 (23b) 80°C, 24 h No conv. 
3 H-Tyr-Phe(4-Br)-NH2 (23c) 80°C, 24 h No conv. 
4 H-Ala-Phe(4-Br)-NH2 (23d) MW, 140°C, 20 min No conv. 
5 H-Ala-Phe(4-Br)-NH2 (23d) MW, 140°C, 60 min No conv. 
6
 H-Ser-Phe(4-I)-NH2     (24a) 80°C, 6 h 95% (30%)
[c]
 
7 H-Leu-Phe(4-I)-NH2   (24b) 80°C, 2 h 99% (40%) 
8 H-Tyr-Phe(4-I)-NH2    (24c) 80°C, 2 h 95% (41%) 
9 H-Ala-Phe(4-I)-NH2    (24d) 80°C, 2 h 90% (49%)
[c]
 
 [a] Reaction conditions: Substrate (0.02 mmol, 23a-d or 24 a-d), 5 mol% 5a, 
phenylboronic acid (2.5 eq), K2CO3 (5 eq), 50% iPrOH in H2O (1 mL). [b] 
Measured by HPLC (215 nm, uncorrected). [c] Isolation by prep HPLC. 
Evaluation of unprotected halotryptophan as substrates in 
Suzuki-Miyaura reactions.  
In order to verify whether another aromatic core would present a 
similar reactivity, we evaluated brominated tryptophans that 
were readily available via a biotransformation protocol,[11a] and 
dipeptides containing this moiety as substrates (Table 8). 
Halotryptophans were previously investigated as substrates for 
Suzuki-Miyaura reaction.[5a,7a] In this work, various precatalysts 
on unprotected 5-bromotryptophan (26a) and selected 
tryptophan dipeptides were evaluated. High conversions on the 
unprotected dipeptides were obtained with the 
[Na2ADHP]2Pd(OAc)2 precatalyst 1a (Table 8, entry 1). In this 
case the PdCl2(dppf) precatalyst 5a however did not give rise to 
high conversions (Table 8, entry 6). In order to achieve 
Table 7. Evaluation of C-terminal dipeptide amides (23a-d, 24a-d) as 
substrates in Suzuki-Miyaura reaction.  
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satisfactory conversion, the amount of PhB(OH)2 had to be 
increased to 2.5 eq.  
Entry Cat. Substrate Solvent Time /h Conv. /% 
[a,b] 
Yield /%  
1 1a 26a H2O 2 h 90% (54%)
[c]
 
2 1b 26a H2O 2 h 57%  
3 2 26a H2O 24 h 46%  
4 4a 26a H2O 2 h 65%  
5 4b 26a H2O 2 h 25%  
6 5a 26a aq. 50% iPrOH 2 h 9%  
7 1a 27a H2O 2 h 89% (33%)
[c]
 
8 1a 27b H2O 24 h 60% (24%)
[c]
 
9 1a 27c H2O 4 h 80% (29%)
[c]
 
[a] Reaction conditions: tryptophan bromide (26a, 27a-c) (0.05-0.08 mmol), 5 
mol% catalyst, phenylboronic acid (2.5 eq), K2CO3 (5 or 6 eq), H2O (2 mL), 
80°C. [b] Measured by HPLC (215 nm). [c] Isolated by preparative HPLC. 
By using 1a as a catalyst, it is now possible to isolate derivatised 
tryptophan dipeptides without protecting groups (29a-c). 
Furthermore, we verified whether this precatalyst was also able 
to perform the cross-coupling on other regioisomers of 
bromotryptophan (Table 9). Therefore, we tested 6-bromo- (26b) 
and 7-bromotryptophan (26c) and gratifyingly good conversions 
could be achieved (Table 9, entries 1 and 2). Access to 7-
iodotryptophan (30)[11a] enabled the preparation of 7-
vinyltryptophan (31), which in turn permits further derivatisation 
via the vinyl moiety (entry 4). In this case 5a was a suitable 
precatalyst.  
 
 
 
 
 
 
 
 
Entry Cat. Substrate Solvent R Conv. /% 
[a,b]
 
Yield /% 
1 1a 26b H2O phenyl 70% (38%)
[d]
 
2 1a 26c H2O phenyl 95% (44%)
[d]
 
3
[c]
 5a 26c aq. 50% iPrOH vinyl No conversion 
4
[c]
 5a 30 aq. 50% iPrOH vinyl 80% (29%)
[d]
 
 [a] Reaction conditions: tryptophan halide (26b-c, 30) (0.08 mmol), 5 mol% 
catalyst, phenylboronic acid (2.5 eq), K2CO3 (5 eq), H2O (2 mL), 2 h, 80°C. [b] 
Measured by HPLC (215 nm, uncorrected). [c] Reaction time was 4 h. [d] 
Isolated by preparative HPLC. 
Conclusions 
A facile system for the derivatisation of unprotected 
halogenated phenylalanines, tryptophans and dipeptides, 
containing these amino acids, is described in water or mixed 
water/iPrOH as solvent. Compared to the previously reported 
catalytic systems for aqueous media, the PdCl2(dppf) catalyst 
shows an increased tolerance for a broad range of side chain 
functionalities, including primary amide and imidazole moieties, 
without the need for protecting groups. Various (hetero)aromatic 
boronic acids reagents can be used and lead to molecules which 
can be used directly as building blocks in peptide synthesis. 
Interestingly, the PdCl2(dppf) system also enabled access to 
unprotected vinylated amino acids. 
 
 
 
 
 
 
Table 8. Preliminary screening with 5-bromotryptophan (26a) and 5-
bromotryptophan containing dipeptides (27a-c) as substrates in the Suzuki-
Miyaura reaction.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. Regioisomeric bromotryptophan (26b,c) and 7-IodoTrp (30) as 
substrates in the Suzuki-Miyaura reaction.  
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Experimental Section 
General 
Column chromatography purifications were conducted with silica gel 60 
(40-63 µm; Grace Davisil). TLC was carried out on glass plates 
precoated with silica gel 60F254 (Merck); the spots were visualised 
under UV light (λ= 254 nm) and/or a KMnO4 (aq.) solution was used to 
reveal spots. The used HPLC system consisted of Waters 1525 Binary 
HPLC pumps and a Waters 2487 dual absorbance wavelength detector, 
with detection set at 215 nm and 254 nm, connected to an auto-sampler. 
All HPLC analyses were performed on this equipment, unless stated 
otherwise. Upon use of “system 2”, a similar setup, without an auto-
sampler, was used. A Grace Vydac C18 (25 cm x 4.6 mm x 5 m) 
reversed phase column was employed in both systems. The solvent 
system consisted of water (with 0.1 % TFA)/acetonitrile (with 0.1 % TFA) 
mixtures. In general, the samples were dissolved in water/acetonitrile 
(1:1) and eluted with a standard gradient going from 3 % to 100 % AcN in 
20 minutes, and with a flow rate of 1 ml/min. Preparative HPLC was 
conducted on a Gilson preparative HPLC system mounted with a 
Supelco Discovery Bio Wide Pore C18 column. 1H NMR and 13C NMR 
spectra were recorded on a Bruker Avance DRX 250 console and a 
Bruker Avance II 500 console at 250 or 63 MHz and 500 or 126 MHz, 
respectively. The deuterated solvent is mentioned for each individual 
spectra. Chemical shifts (δ) are presented in parts per million (ppm), 
while coupling constants (J) are given in Hertz (Hz). High resolution mass 
spectrometry was conducted on a Waters Micromass QTof system in 
ES+ mode, using reserpine as the reference. Reagents were used as 
purchased from Sigma Aldrich (catalysts and general chemicals), 
Chemimpex (amino acid derivatives) or ABCR (general chemicals). The 
halogenated tryptophans were obtained via a biotransformation protocol 
as described in Smith. D. et al.[11a] The amino acids all possessed the L-
configuration. The Suzuki-Miyaura reactions were run in mQ water and, 
where applicable, HPLC grade iPrOH was used.  
Preparation of catalysts 
All catalysts, except 1a, 1b and 3, were used as obtained from their 
respective commercial source. Precatalyst 5b was a kind gift from the 
ORSY research group, University of Antwerp. For 1a and 1b, the 0.01 M 
catalyst solution was prepared as described by Davis and coworkers.[5d] 
Sulfonated SPhos (3) was prepared starting from SPhos as described by 
Buchwald and coworkers.[3c] Spectra were consistent with literature 
data.[3c] Ligand 3 was obtained as a yellow solid in 82 % yield (102 mg). 
MS (ES+): 491 [M+H+] (MW 490.6 g/mol, as sulfonic acid; 1H-NMR (250 
MHz, D2O): δH 6.87-7.89 (6H, M), 3.70 (3H, s), 3.35 (3H, s), 0.87-2.01 
(22H, m). 
General procedure for the evaluation of ligands in the 
Suzuki-Miyaura coupling  
To a solution of 6a-c (25 mg, 0.102 mmol), K2CO3 (70.8 mg, 0.510 mmol) 
and phenylboronic acid (14.9 mg, 0.123 mol) in H2O (2 mL) the 
respective catalyst (5 mol%, 5.1 µmol) was added. The solution was 
stirred for the reported reaction time (see Table 1) at 80°C in a sealed 10 
mL vial. HPLC analysis was performed by taking an aliquot (10 µL) of the 
reaction mixture and further dilution to 1 mL with a H2O/AcN (1:1) mixture. 
 
 
 
 
Solvent ratio evaluation 
A 10 mL microwave vial was charged with 6a (50 mg, 0.205 mmol) or 8a 
(50 mg, 0.145 mmol), phenylboronic acid (1.2 eq), K2CO3 (5 eq) and 5a 
(1 mol%), and fitted with a stirring bar. A mixture of H2O and iPrOH was 
added consecutively (to give a total volume of 4 mL, see Table 2). The 
reaction mixture was heated to 80°C for 24 (6a) or 2 hours (8a). HPLC 
analysis was performed by taking an aliquot (10 µL) of the reaction 
mixture and further dilution to 1 mL with a H2O/AcN (1:1) mixture.  
Evaluation of boronic acid scope with PdCl2(dppf) 
General procedure A 
For unprotected substrates, 6a (25 mg, 0.102 mmol) was dissolved 
together with the respective boronic acid (1.2 eq, 0.123 mmol), K2CO3 
(70.8 mg, 0.510 mmol) and PdCl2(dppf) 5a (4.2 mg, 5.1 µmol) in a 
mixture of H2O and iPrOH (1:1, total 2 mL). The 10 mL microwave vial 
was fitted with a stirring bar and closed with a crimp cap. The reaction 
mixture was heated to 80°C for 4 hours. After cooling to RT, the reaction 
mixture was concentrated by rotary evaporation. The residue was 
dissolved in H2O (20 mL) and washed with CH2Cl2 (2x 10 mL). The 
aqueous phase was concentrated and redissolved in a mixture of H2O 
and AcN (5:1) and purified by preparative HPLC (gradient 0-60 % AcN in 
H2O over 20 mins, supplemented with 0.1 % TFA). The obtained 
solutions were lyophilised to obtain 7a-j (TFA salts) as white powders. 
General procedure B 
For protected substrates, 8a (688 mg, 2 mmol) was dissolved together 
with the respective boronic acid (1.2 eq, 2.4 mmol), K2CO3 (1.382 g, 10 
mmol) and 5a (16.5 mg, 0.02 mmol) in a mixture of H2O and iPrOH (19:1, 
total 20 mL) in a 50 mL flask, equipped with a stirring bar and a reflux 
condenser. The reaction mixture was heated to 80°C for 60 mins. After 
cooling to RT, iPrOH was removed by rotary evaporation and carefully 
acidified with 5 N HCl to pH= 3, as indicated by pH paper. The aqueous 
phase was extracted with CH2Cl2 (4x 25 mL). The combined organic 
layers were dried over MgSO4 and concentrated by evaporation. The 
crude was purified by column chromatography with a mixture of ethyl 
acetate and petroleum ether, supplemented with 2 % of acetic acid. The 
combined fractions were concentrated under high vacuum and 
lyophilised to obtain 9a-j as white solids to yellow solids. 
Preparation of H-Phe(4-phenyl)-OH (7a) 
Compound 7a was prepared via general procedure A to give a white 
powder in 48 % yield (16.6 mg). HPLC: tR = 12.3 min; HRMS: [M+H]
+ 
calculated 242.1176 found 242.1177; 1H-NMR (500 MHz, CD3OD): δH 
7.59-7.65 (4H, m), 7.44 (2H, t, J= 7.6 Hz), 7.38 (2H, d, J= 8.1 Hz), 7.32-
7.36 (1H, m), 4.24 (1H, t, J= 6.0 Hz), 3.37 (1H, dd, J=14.6 Hz, 5.0 Hz), 
3.19 (1H, dd, J= 14.5 Hz, 7.7 Hz); 13C-NMR (63 MHz, DMSO-d6): δC 
170.4, 139.8, 139.1, 134.1, 130.1, 129.0, 127.5, 126.8, 126.6, 53.1, 35.5. 
Preparation of H-Phe(3-phenyl)-OH (7b) 
Compound 7b was prepared according to general procedure A and 
obtained as a white powder in 41 % yield (14.3 mg). HPLC: tR = 12.6 
min; HRMS: [M+H]+ calculated 242.1176 found 242.1190; 1H-NMR (500 
MHz, DMSO-d6): δH 7.66 (2H, d, J= 7.3 Hz), 7.54-7.58 (2H, m), 7.46 (2H, 
t, J= 7.6 Hz), 7.41 (1H, t, J= 7.9 Hz), 7.36 (1H, t, J= 7.3 Hz), 7.25 (1H, d, 
J= 7.5 Hz), 4.15 (1H, t, J= 6.1 Hz), 3.20 (1H, dd, J= 14.3 Hz, 5.6 Hz), 
3.13 (1H, dd, J= 14.2 Hz, 6.7 Hz); 13C-NMR (126 MHz, DMSO-d6): δC 
170.4, 140.4, 140.1, 135.9, 129.1, 128.9, 128.6, 128.1, 127.5, 126.8, 
125.5, 53.5, 36.0. 
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Preparation of H-Phe(2-phenyl)-OH (7c) 
Compound 7c was prepared according to general procedure A as a white 
powder in 38 % yield (13.0 mg). HPLC: tR = 12.1 min; HRMS: [M+H]
+ 
calculated 242.1176 found 242.1167; 1H-NMR (500 MHz, DMSO-d6): δH 
8.13 (2H, br s), 7.26-7.47 (8H, M), 7.18 (1H, dd, J= 7.2 Hz, 1.4 Hz), 3.75 
(1H, t, J= 7.6 Hz), 3.15 (1H, dd, J= 14.4 Hz, 7.6 Hz), 2.96 (1H, d, J= 14.4 
Hz, 7.6 Hz); 13C-NMR (126 MHz, DMSO-d6): δC 170.3, 142.1, 140.6, 
132.7, 130.1, 129.7, 129.0, 128.3, 127.6, 127.1, 127.0, 52.6, 33.6. 
Preparation of H-Phe(4-p-methoxyphenyl)-OH (7d) 
Compound 7d was prepared according to general procedure A as a 
white powder in 33 % yield (12.6 mg). HPLC: tR = 12.3 min; HRMS: 
[M+H]+ calculated 272.1281 found 272.1286. 1H-NMR (500 MHz, DMSO-
d6): δH 8.31 (2H, br s), 7.54-7.63 (4H, m), 7.31 (2H, d, J= 7.1 Hz), 7.01 
(2H, d, J= 8.8 Hz), 4.21 (1H, t, J= 6.3 Hz), 3.78 (3H, s), 3.08-3.15 (2H, 
m);13C-NMR (126 MHz, DMSO-d6): δC 170.4, 158.9, 138.7, 133.2, 132.1, 
130.0, 127.6, 126.3, 114.4, 55.2, 53.1, 35.4. 
Preparation of H-Phe(4-p-trifluoromethylphenyl)-OH (7e) 
Compound 7e was prepared according to general procedure A as a white 
powder in 45 % yield (18.6 mg). HPLC: tR = 14.1 min; HRMS: [M+H]
+ 
calculated 310.1049 found 310.1053. 1H-NMR (250 MHz, DMSO-d6): δH 
ppm 8.36 (2H, br s), 7.89 (2H, d, J= 8.2 Hz), 7.80 (2H, d, J= 8.4 Hz), 7.72 
(2H, d, J= 8.0 Hz), 7.40 (2H, d, J= 8.1 Hz), 4.24 (1H, t, J= 6.2 Hz), 3.16 
(2H, d, J= 6.2 Hz); 13C-NMR (63 MHz, DMSO-d6): δC 170.4, 143.7, 137.4, 
135.4, 130.3, 127.3, 127.2, 125.8 (d, J= 3.7 Hz), 53.1, 35.5. Some 
quaternary carbons not observed. 
Preparation of H-Phe(4-o-tolyl)-OH (7f) 
Compound 7f was prepared according to general procedure A as a white 
powder in 60 % yield (21.8 mg). HPLC: tR = 12.8 min; HRMS: [M+H]
+ 
calculated 256.1332 found 256.1328; 1H-NMR (500 MHz, DMSO-d6): δH 
8.41 (2H, br s), 7.21-7.35 (7H, m), 7.16 (1H, d, J= 6.0 Hz), 4.13-4.20 (1H, 
m), 3.15 (2H, m), 2.22 (3H, s); 13C-NMR (126 MHz, DMSO-d6): δC 170.5, 
140.9, 140.0, 134.7, 133.7, 130.4, 129.3, 129.1, 127.3, 125.9, 53.4, 35.6, 
20.2. 
Preparation of H-Phe(4-indol-5-yl)-OH (7g) 
Compound 7g was prepared according to general procedure A as a 
white powder in 37 % yield (14.5 mg). HPLC: tR = 11.7 min; HRMS: 
[M+H]+ calculated 281.1285 found 281.1288; 1H-NMR (500 MHz, DMSO-
d6): δH 11.1 (1H, m), 10.98 (1H, s), 8.29 (2H, br s), 7.59-7.83 (2H, M), 
7.52-7.57 (1H, m), 7.42-7.48 (1H, M), 7.22-7.41 (5H, M), 4.16-4.25 (1H, 
m), 3.06-3.15 (2H, m, overlap with H2O); 
13C-NMR (126 MHz, DMSO-d6): 
δC 170.4, 140.8, 136.5, 135.5, 132.5, 129.9, 126.8, 126.1, 125.8, 120.2, 
117.9, 111.8, 101.5, 53.2, 35.4. 
Preparation of H-Phe(4-furan-3-yl)-OH (7h) 
Compound 7h was prepared according to general procedure A as a 
white powder in 33 % yield (11.0 mg). HPLC: tR = 11.0 min; HRMS: 
[M+H]+ calculated 232.0968 found 232.0965; 1H-NMR (500 MHz, DMSO-
d6): δH 8.25 (2H, br s), 8.18 (1 H, s), 7.73 (1H, s), 7.58 (1H, d, J= 7.9 
Hz), 7.26 (2H, d, J= 8.1 Hz), 6.95 (1H, s), 4.16-4.24 (1 H, m), 3.05-3.12 
(2H, m); 13C-NMR (63 MHz, DMSO-d6): δC 170.4, 144.3, 139.2, 134.0, 
130.8, 130.0, 125.7, 125.6, 108.7, 53.7, 35.8. 
 
Preparation of H-Phe(4-thien-3-yl)-OH (7i) 
Compound 7i was prepared according to general procedure A as a white 
powder in 39 % yield (13.7 mg). HPLC: tR = 11.9 min; HRMS: [M+H]
+ 
calculated 248.0740 found 248.0732; 1H-NMR (500 MHz, DMSO-d6): δH 
8.36 (2H, br s), 7.85 (1H, d, J= 1.5 Hz), 7.67 (2H, d, J= 7.9 Hz), 7.59-7.64 
(1H, m), 7.49-7.58 (1H, d, J= 4.7 Hz), 7.29 (2H, d, J= 7.5 Hz), 4.11-4.25 
(1H, m), 3.06-3.17 (2H, m); 13C-NMR (126 MHz, DMSO-d6): δC 170.2, 
141.0, 134.0, 133.6, 129.9, 127.0, 126.1, 126.0, 120.7, 53.1, 35.4. 
Preparation of H-Phe(4-vinyl)-OH (7j) 
Compound 7j was prepared according to general procedure A from 10a 
(29.8 mg, 0.102 mmol) as a white powder in 40 % yield (11.8 mg). 
HPLC: tR = 11.7 min; HRMS: [M+H]
+ calculated 192.1019 found 
192.1009; 1H-NMR (500 MHz, DMSO-d6): δH 8.27 (2H, br s), 7.43 (2H, d, 
J= 7.9 Hz), 7.23 (2H, d, J= 7.9 Hz), 6.72 (2H, dd, J= 17.6 Hz, 11.0 Hz), 
5.82 (1H, d, J= 17.5 Hz), 5.24 (1H, d, J= 11.1 Hz), 4.14 (1H, t, J= 6.3 Hz), 
3.03-3.12 (2H, m); 13C-NMR (126 MHz, DMSO-d6): δC 170.3, 136.3, 
136.1, 134.6, 129.7, 126.3, 114.2, 53.2, 35.6. 
Preparation of Boc-Phe(4-phenyl)-OH (9a) 
Compound 9a was prepared according to general procedure B as a white 
solid in 83 % yield (565 mg). The crude was purified with silica column 
chromatography with petroleumether/EtOAc 2:1 + 2 % AcOH. Rf: 0.26 
(p.e./EtOAc 2:1 + 2 % AcOH); HPLC: tR = 17.6 min; HRMS: [M+Na]
+ 
calculated 364.1519 found 364.1532; 1H-NMR (250 MHz, DMSO-d6): δH 
12.62 (1H, br s), 7.63 (2H, d, J= 8.0 Hz), 7.57 (2H, d, J= 8.0 Hz), 7.39-
7.48 (2H, m), 7.27-38 (3H, m), 7.14 (1H, d, J= 8.4 Hz), 4.11 (1H, td, J= 
9.2 Hz, 4.5 Hz), 3.05 (1H, dd, J= 13.7 Hz, 4.4 Hz), 2.85 (1H, dd, J= 13.4 
Hz, 10.6 Hz), 1.31 (9H, s); 13C-NMR (63 MHz, DMSO-d6): δC 173.6, 
155.5, 140.0, 138.2, 137.3, 129.7, 128.9, 127.2, 126.5, 126.4, 78.1, 55.1, 
36.0, 28.1. 
Preparation of Boc-Phe(4-p-methoxyphenyl)-OH (9b) 
Compound 9b was prepared according to general procedure B as a 
white solid in 88 % yield (652 mg). The crude was purified with silica 
column chromatography with petroleumether/EtOAc 3:1 + 2 % AcOH). 
Rf: 0.30 (p.e./EtOAc 2:1 + 2 % AcOH); HPLC: tR = 17.4 min; HRMS: 
[M+Na]+ calculated 394.1625 found 394.1631; 1H-NMR (250 MHz, 
DMSO-d6): δH 12.60 (1H, br ), 7.57 (2H, d, J= 8.5 Hz), 7.51 (2H, d, J= 
8.1 Hz), 7.29 (2H, d, J= 8.0 Hz), 7.11 (1H, d, J= 8.2 Hz), 6.99 (2H, d, J= 
8.6 Hz), 4.03-4.17 (1H, m), 3.77 (3H, s), 3.03 (1H, dd, J= 13.7 Hz, 4.3 
Hz), 2.84 (1H, dd, J= 13.4 Hz, 10.6 Hz), 1.31 (9H, s); 13C-NMR (63 MHz, 
DMSO-d6): δC 173.6, 158.8, 155.5, 137.9, 136.5, 132.4, 129.6, 127.6, 
125.9, 114.3, 78.0, 55.2, 55.1, 36.0, 28.2. 
Preparation of Boc-Phe(4-p-trifluoromethylphenyl)-OH (9c) 
Compound 9c was prepared according to general procedure B as a white 
solid 79 % yield (644 mg). The crude was purified with silica column 
chromatography with petroleumether/EtOAc 4:1 +2 % AcOH). Rf: 0.30 
(p.e./EtOAc 3:1 + 2 % AcOH); HPLC: tR = 19.0 min; HRMS: [M-Boc]
+ 
calculated 310.1049 found 310.1062; 1H-NMR (250 MHz, DMSO-d6): δH 
12.65 (1H, s), 7.87 (2H, d, J= 8.4 Hz), 7.78 (2H, d, J= 8.5 Hz), 7.66 (2H, 
d, J= 8.1 Hz), 7.38 (2H, d, J= 8.1 Hz), 7.17 (1H, d, J= 8.5 Hz), 4.12 (1H, 
td, J= 9.5 Hz, 4.3 Hz), 3.07 (1H, dd, J= 13.8 Hz, 4.3 Hz), 2.87 (1H, dd, J= 
13.6 Hz, 10.7 Hz), 1.30 (9H, s); 13C-NMR (63 MHz, DMSO-d6): δC 173.5, 
155.5, 144.0, 138.6, 136.6, 129.9, 127.3, 126.8, 125.8 (d, J= 3.7 Hz), 
78.1, 55.1, 361, 28.2; 19F-NMR (236 MHz, DMSO-d6) δF -60.83. Some 
quaternary carbons not observed. 
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Preparation of Boc-Phe(4-o-tolyl)-OH (9d) 
Compound 9d was prepared according to general procedure B as a 
white powder in 85 % yield (603 mg). The crude was purified with silica 
column chromatography with petroleumether/EtOAc 4:1 + 2 % AcOH). 
Rf: 0.31 (p.e./EtOAc 3:1 + 2 % AcOH); HPLC: tR = 18.3 min; HRMS: 
[M+Na]+ calculated 378.1676 found 378.1666; 1H-NMR (250 MHz, 
DMSO-d6): δH 12.63 (1H, br s), 7.07-7.40 (9H, M), 4.03-4.24 (1H, m), 
3.07 (1H, dd, J= 13.8 Hz, 4.2 Hz), 2.86 (1H, dd, J= 13.4 Hz, 11.0 Hz), 
2.20 (3H, s), 1.31 (9H, s); 13C-NMR (63 MHz, DMSO-d6): δC 173.6, 
155.5, 141.1, 139.3, 136.7, 134.7, 130.3, 129.5, 129.0, 128.7, 127.2, 
125.9, 78.0, 55.0, 36.2, 28.1, 20.2. 
Preparation of Boc-Phe(4-indol-5-yl)-OH (9e) 
Compound 9e was prepared according to general procedure B as a white 
powder in 89 % yield (676 mg). The crude was purified with silica column 
chromatography with petroleumether/EtOAc 2:1 +2 % AcOH). Rf: 0.51 
(p.e./EtOAc 1:1+ 2 % AcOH); HPLC: tR = 16.2 min; HRMS: [M+Na]
+ 
calculated 403.1628 found 403.1622; 1H-NMR (250 MHz, DMSO-d6): δH 
12.67 (1H, br s), 11.12 (1H, br s), 7.77 (s, 1H), 7.56 (2H, d, J= 8.0 Hz), 
7.41-7.48 (1H, m), 7.22-7.40 (4H, M), 7.09 (1H, d, J= 8.2 Hz), 6.46 (1H, 
s), 4.11 (1H, td, J= 9.0 Hz, 4.5 Hz), 3.05 (1H, dd, J= 13.7 Hz, 4.4 hz), 
2.85 (1H, dd, J= 13.6 Hz, 10.3 Hz), 1.32 (9H, s); 13C-NMR (63 MHz, 
DMSO-d6): δC 173.6, 155.5, 139.9, 135.9, 135.4, 131.2, 129.5, 128.2, 
126.4, 126.0, 120.2, 117.9, 111.7, 101.5, 78.0, 55.3, 36.1, 28.2. 
Preparation of Boc-Phe(4-furan-3-yl)-OH (9f) 
Compound 9f was prepared according to general procedure B as a white 
powder in 84 % yield (557 mg). The crude was purified with silica column 
chromatography with petroleumether/EtOAc 1:1 + 2 % AcOH). Rf: 0.20 
(p.e./EtOAc 1:1 + 2 % AcOH); HPLC: tR = 16.5 min; HRMS: [M+Na]
+ 
calculated 354.1312 found 354.1328; 1H-NMR (250 MHz, DMSO-d6): δH 
12.61 (1H, br s), 8.13 (1H, s), 7.71 (1H, s), 7.51 (2H, d, J= 8.0 Hz), 7.25 
(2H, d, J= 8.0 Hz), 7.10 (1H, d, J= 8.3 Hz), 6.92 (1H, m), 4.09 (1H, m), 
3.01 (1H, dd, J= 13.8 ,4.5 Hz), 2.83 (1H, dd, J= 13.8 ,10.4 Hz), 1.31 (9H, 
s); 13C-NMR (63 MHz, DMSO-d6): δC 173.6, 155.5, 144.2, 139.0, 136.7, 
130.0, 129.6, 125.7, 125.3, 108.7, 78.1, 55.2, 36.1, 28.2. 
Preparation of Boc-Phe(4-thien-3-yl)-OH (9g) 
Compound 9g was prepared according to general procedure B as a 
white powder in 89 % yield (618 mg). The crude was purified with silica 
column chromatography with petroleumether/EtOAc 2:1 + 2 % AcOH). 
Rf: 0.39 (p.e./EtOAc 1:1 + 2 % AcOH); HPLC: tR = 17.1 min; HRMS: 
[M+Na]+ calculated 370.1083 found 370.1070; 1H-NMR (250 MHz, 
DMSO-d6): δH 12.62 (1H, s), 7.81 (1H, m), 7.50-7.65 (4H, M), 7.27 (2H, d, 
J= 8.0 Hz), 7.11 (1H, d, J= 8.4 Hz), 4.03-4.14 (1H, m), 3.02 (1H, dd, J= 
13.6 Hz, 4.3 Hz), 2.83 (1H, dd, J= 13.4 Hz, 10.7 Hz), 1.31 (9H, s); 13C-
NMR (63 MHz, DMSO-d6): δC 173.6, 155.5, 141.3, 136.9, 133.3, 129.6, 
127.0, 126.1, 125.9, 120.5, 78.1, 55.2, 36.1, 28.2. 
Preparation of Boc-Phe(4-vinyl)-OH (9h) 
Compound 11a was dissolved (782 mg, 2 mmol) together with potassium 
vinyltrifluoroborate (321 mg, 2.4 mmol), K2CO3 (1.382 mg, 10 mmol) and 
5a (16.5 mg, 0.02 mmol) in a mixture of H2O and iPrOH (1:1, total 20 mL). 
The solution was heated to 80°C for 1 hour. Work-up was similar as 
described in general procedure B. The crude was purified by silica 
column chromatography (CH2Cl2/MeOH/AcOH 97:1:2) and lyophilised. 
9h was obtained as a yellow solid in 81 % yield (471 mg). Rf: 0.25 
(CH2Cl2/MeOH/AcOH 97:1:2). HPLC: tR = 16.9 min; HRMS: [M+Na]
+ 
calculated 314.1363 found 314.1378; 1H-NMR (500 MHz, DMSO-d6): δH 
12.56 (1H, br s), 7.36 (2H, d, J= 7.5 Hz), 7.20 (2H, d, J= 7.5 Hz), 7.07 
(1H, d, J=8.3 Hz), 6.68 (1H, dd, J= 17.4 Hz, 11.0 Hz), 5.77 (1H, d, J= 
17.5 Hz), 5.19 (1H, d, J= 10.9 Hz), 4.01-4.12 (1H, m), 2.98 (1H, dd, 
J=13.7 Hz, 3.9 Hz), 2.80 (1H, dd, J= 12.9 Hz, 10.8 Hz,) 1.30 (9H, s). 13C-
NMR: (126 MHz, DMSO-d6): δC: 173.6, 137.9, 136.5, 135.3, 129.4, 
126.0, 113.7, 78.1, 55.1, 36.2, 28.2. 
Preparation of Boc-Phe(3-vinyl)-OH (9i) 
Compound 9i was prepared starting from 11b following the procedure as 
described for 9h. After column chromatography, the product was 
obtained as a white solid in 89 % yield (520 mg). Rf: 0.22 
(CH2Cl2/MeOH/AcOH 97:1:2); HPLC: tR = 16.9 min; HRMS: [M+Na]
+ 
calculated 314.1363 found 314.1377; 1H-NMR (500 MHz, CDCl3): δH 
10.72 (1H, br s), 7.23-7.32 (3H, M), 7.10 (1H, s), 6.70 (1H, dd, J= 17.5 
Hz, 10.9 Hz), 6.58-6.63 (1H, m, [B])*, 5.75 (1H, d, J= 17.5 Hz), 5.25 (1H, 
d, J= 10.9 Hz), 5.02 (1H, d, J= 6.2 Hz, [A])*, 4.59-4.67 (1H, m, [A])*, 4.38-
4.46 (1H, m, [B])*, 3.17-3.25 (1H, m), 3.05-3.12 (1H, m, [A])*, 2.87-2.95 
(1H, m, [B])*, 1.43 (9H, s, [A])*, 1.29 (9H, s, [B])*; 13C-NMR (126 MHz, 
CDCl3): δC 176.7 [A] and 176.3 [B]*, 156.8 [B] and 155.6 [A]*, 137.8, 
136.6, 136.1, 129.0, 128.7, 127.3, 124.9 [A] and 124.8 [B]*, 114.0, 81.6 
[B] and 80.3 [A]*, 56.0 [A] and 54.2 [B]*, 39.2 [A] and 37.7 [B]*, 28.3 [A] 
and 27.9 [B]*. *Rotamers observed on 1H-NMR and 13C-NMR. At 25°C, 
two rotamers ([A]: major, [B]: minor) in approximately 64:36 ratio were 
visible. 
Preparation of Boc-Phe(2-vinyl)-OH (9j) 
Compound 9j was prepared starting from 11c following the procedure as 
described for 9h. After column chromatography, the product was 
obtained as a white solid in 89 % yield (517 mg). Rf: 0.24 
(CH2Cl2/MeOH/AcOH 97:1:2); HPLC: tR = 17.0 min; HRMS: [M+Na]
+ 
calculated 314.1363 found 314.1367; 1H-NMR (500 MHz, CDCl3): δH 
11.56 (1H, br s), 7.52-7.59 (1H, m), 7.18-7.32 (4H, M), 7.04-7.16 (1H, m), 
5.68-5.77 (1H, m), 5.38 (1H, d, J= 10.9 Hz), 5.05 (1H, d, J= 7.3 Hz, [B]), 
4.61 (1H, m, [B]), 4.45-4.52 (1H, m, [A]),1.44 (9H, s, [B]), 1.17 (9 H, s, 
[A]); 13C-NMR (63 MHz, DMSO-d6): δC 176.6 [B] and 175.5 [A]*, 156.7 
[A] and 155.2 [B]*, 137.5 [B] and 137.2 [A]*, 134.4 [A] and 133.4 [B]*, 
134.2 [B] and 133.9 [A]*, 131.1 [A] and 130.3 [B]*, 127.8, 127.4 [B] and 
127.2 [A], 126.2 [B] and 125.7 [A]*, 116.6 [B] and 116.1 [A]*, 81.3 [A] and 
80.1 [B]*, 55.2 [A] and 54.2 [B]*, 38.1 [A] and 35.3 [B]*, 28.5 [B] and 28.0 
[A]*. *Rotamers observed on 1H-NMR and 13C-NMR. At 25°C, two 
rotamers ([A]: major, [B]: minor) in approximately 66:33 ratio were visible. 
Dipeptide experiments with 0.01 M [Na2(ADHP)]2.Pd(OAc)2 
Dipeptide synthesis of H-AA-Phe(4-Br)-OH (12a-12m) 
Dipeptide carboxylic acids were synthesised on 2-Cl-tritylchloride resin 
(obtained from GL Biochem or Chemimpex) following standard Fmoc-
based solid-phase peptide synthesis (SPPS) in a polypropylene syringe 
with polyethylene frit using SPPS grade CH2Cl2 or DMF. The protocol 
was started by swelling the resin in DMF for 30 mins and followed by 
coupling the first amino acid (Fmoc-4-Br-Phe, 2 eq) with DIPEA (4 eq) in 
DMF for 90 mins. Reagents were filtered and the resin was washed with 
DMF, iPrOH and CH2Cl2 (each 3x 1 min). The resin was treated with a 
mixture of MeOH, CH2Cl2 and DIPEA (2:17:1) for endcapping (4x 5 min). 
After washing, the Fmoc protecting group was removed by treating the 
resin with 20 % 4-methylpiperidine in DMF (5 min, 15 min). After washing, 
the second amino acid (either as Boc-AA-OH or Fmoc-AA(Pg)-OH was 
coupled (3 eq) with HCTU (3 eq) in 0.4 M NMM for 60 mins. The excess 
reagents were removed by filtration and the resin was washed. The 
Kaiser ninhydrin test was used to check for complete conversion. If 
complete coupling was observed, the resin was treated with 20 % 4-
methylpiperidine in DMF (in the case Boc-AA-OH was coupled, this 
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deprotection step was not necessary) for 5 mins and 15 mins. Upon 
completion of the peptide assembly, the resin was washed and treated 
with a standard cleavage cocktail (95 % TFA and 5 % H2O)
1 for 2 hours.2 
The deprotected peptide was collected by filtration, concentrated in 
vacuo and purified over a C-18 cartridge (Supelco) while eluting with 
H2O/AcN (5:1). Afterwards, the dipeptides were lyophilised and obtained 
as white to off-white powders, identification and purity were determined 
by HPLC and LC/MS analysis. As such, the dipeptides were prepared as 
their corresponding TFA salts. 
1In the case of Trp, Asn, His, Arg the cleavage cocktail was altered to 
95 % TFA, 2.5 % H2O and 2.5 % triethylsilane. 
23 hours in the case of Arg for complete pbf deprotection.  
Entry Peptide 
MW 
(g/mol) 
LC/MS 
[M+H,
81
Br]
+ 
HPLC  
(min) 
[a]
 
1 H-Gly-Phe(4-Br)-OH 12a 301.1 303 9.2 
2  H-Ala-Phe(4-Br)-OH 12b 315.2 317 9.2 
3  H-Leu-Phe(4-Br)-OH 12c 357.2 359 10.5 
4  H-Ser-Phe(4-Br)-OH 12d 331.2 333 9.1 
5  H-Asp-Phe(4-Br)-OH 12e 359.2 361 9.3 
6  H-Lys-Phe(4-Br)-OH 12f 372.3 374 8.6 
7  H-Phe-Phe(4-Br)-OH 12g 391.3 393 10.7 
8  H-Tyr-Phe(4-Br)-OH 12h 407.3 409 9.9 
9  H-Trp-Phe(4-Br)-OH 12i 430.3 432 11.2 
10 H-Asn-Phe(4-Br)-OH 12j 358.2 360 9.1 
11 H-Met-Phe(4-Br)-OH 12k 375.3 377 10.2 
12 H-His-Phe(4-Br)-OH 12l 381.2 383 8.6 
13 H-Arg-Phe(4-Br)-OH 12m 400.3 402 8.9 
[a] Measured by HPLC system 2 (215 nm). 
Suzuki-Miyaura derivatisation of dipeptides 12a-12m 
In a 10 mL vial, dipeptide bromide (12a-12m, 0.063 mmol) was dissolved 
in H2O (1.7 mL) together with phenylboronic acid (19.1 mg, 0.157 mmol), 
K2CO3 (43.4 mg, 0.312 mmol or 52.1 mg, 0.374 mmol for entries 6, 12 
and 13). The vial was fitted with a stirring bar and the 0.01 M 1a solution 
(315 µL, 3.15 µmol) was added with a syringe. The reaction mixture was 
heated to 80°C. Reaction follow-up was performed by HPLC analysis at 
215 nm. For this analysis, 10 µL aliquot of the reaction mixture was 
diluted to 1 mL with H2O/AcN (1:1). Conversion was calculated based on 
the area under the curve (at 215 nm) by comparison of starting product 
and cross-coupled product peak surface area. LC/MS analysis was 
performed on the crude mixtures to identify the cross-coupled products.  
Entry Peptide 
MW 
(g/mol) 
LC/MS 
[M+H]
+ 
HPLC  
(min) 
[a]
 
1 H-Gly-Phe(4-phenyl)-OH 13a 298.3 299 10.8 
2  H-Ala-Phe(4-phenyl)-OH 13b 312.4 313 10.9 
3  H-Leu-Phe(4-phenyl)-OH 13c 354.5 355 11.7 
4  H-Ser-Phe(4-phenyl)-OH 13d 328.4 329 10.7 
5  H-Asp-Phe(4-phenyl)-OH 13e 356.4 357 10.9 
6  H-Lys-Phe(4-phenyl)-OH 13f 369.5 370 10.2 
7  H-Phe-Phe(4-phenyl)-OH 13g 388.5 389 12.0 
8  H-Tyr-Phe(4-phenyl)-OH 13h 404.5 405 11.4 
9  H-Trp-Phe(4-phenyl)-OH 13i 427.7 428 12.3 
10 H-Asn-Phe(4-phenyl)-OH 13j No coupling observed 
11 H-Met-Phe(4-phenyl)-OH 13k 372.5 373 11.6 
12 H-His-Phe(4-phenyl)-OH 13l No coupling observed 
13 H-Arg-Phe(4-phenyl)-OH 13m 397.4 398 10.4 
[a] Measured by HPLC system 2 (215 nm). 
Synthesis and derivatisation of protected and partially 
unprotected Asn-Phe(4-Br) and His-Phe(4-X) dipeptides 
Preparation of Boc-Asn-Phe(4-Br)-OMe (14a)  
Compound 6a (2.44 g, 10 mmol) was dissolved in MeOH (20 mL, HPLC 
grade) in a 50 mL flask, equipped with a stirring bar. The reaction mixture 
was cooled to 0°C by means of water/ice bath and distilled SOCl2 (2.5 eq, 
1.82 mL, 25 mmol) was added dropwise. After complete addition, the 
water/ice bath was removed and the flask was equipped with a reflux 
condenser and heated to 45°C for overnight reaction. Conversion was 
checked by HPLC and the reaction mixture was concentrated by rotary 
evaporation. The pale yellow solid was washed thoroughly with cold 
diethylether and dried overnight with a high vacuum pump. H-Phe(4-Br)-
OMe was obtained as a pale white solid in 97 % yield (2.86 g, obtained 
as the HCl salt). HPLC: tR = 9.3 min (system 2); MS (ES+): 260 [M+H
+, 
81Br], 258 [M+H+, 79Br] (MW 258.1 g/mol); 1H-NMR (250 MHz, CDCl3): δH 
7.45 (2H, d, J= 15.0 Hz), 7.06 (2H, d, J= 15.0 Hz), 4.22 (1H, t, J= 4.0 Hz), 
3.70 (3H, s), 3.20 (2H, d, J= 4.0 Hz); 13C-NMR (63 MHz, CDCl3): 169.2, 
132.3, 132.2, 130.9, 122.2, 54.0, 53.3, 35.6. 
Spectra for HCl.H-Phe(4-Br)-OMe were consistent with literature data.[29] 
To a solution of HCl.H-Phe(4-Br)-OMe (1.5 g, 5.09 mmol), Boc-Asn-OH 
(1.42 g, 6.11 mmol) and HOBt (1.25 g, 8.15 mmol) in CH2Cl2 (20 mL, 
SPPS grade) was added DIPEA (2.66 mL, 15.28 mmol). The reaction 
mixture was cooled with a water/ice bath to 0°C and a solution of 
EDC.HCl (1.56 g, 8.15 mmol) in CH2Cl2 (5 mL, SPPS grade) was added 
dropwise. After complete addition, the reaction mixture was allowed to 
warm to room temperature and stirred for 16 h. The obtained cloudy 
solution was diluted with CH2Cl2 (25 mL) and filtered over a glass frit. The 
organic phase was washed with saturated NH4Cl (2x 25 mL), aq. sat. 
NaHCO3 (2x 25 mL), water (2x 25 mL) and brine (1x 25 mL). The solution 
was dried over MgSO4 and concentrated by evaporation. The crude was 
suspended in a minimal amount of methanol and filtered over a glass frit. 
After drying overnight with a high vacuum pump, 14a was obtained as a 
white solid in 65 % yield (1.65 g). HPLC: tR = 14.8 min; MS (ES+): 474 
[M+H+, 81Br], 472 [M+H+, 79Br] (MW: 472.3 g/mol); 1H-NMR (250 MHz, 
DMSO-d6): δH 8.14 (1H, d, J= 7.4 Hz), 7.43 (2H, d, J= 8.2 Hz), 7.28 (1H, 
br s), 7.16 (2H, d, J= 9.0 Hz), 6.85-6.90 (2H, M), 4.44 (1H, dd, J= 13.8 Hz, 
6.9 Hz), 4.24 (1H, dd, J= 13.8 Hz, 7.8 Hz), 3.58 (3H, s), 2.86-3.03 (2H, 
m), 2.30 (2H, m), 1.35 (9H, s); 13C-NMR (63 MHz, DMSO-d6): δC 171.8, 
171.5, 171.3, 155.0, 136.4, 131.5, 131.1, 119.8, 78.2, 53.2, 51.9, 51.2, 
37.2, 35.8, 28.2. 
Preparation of Boc-Asn-Phe(4-Br)-OH (14b)  
Compound 14a (150 mg, 0.318 mmol) was dissolved in a mixture of 
THF/H2O (total 2 mL, 7:1) in a 10 mL flask. To this solution was added 
LiOH monohydrate (93 mg, 2.223 mmol) and formic acid (17 µL, 0.445 
mmol). The reaction mixture was stirred for 16 hours. After complete 
conversion of starting material, the reaction mixture was concentrated by 
evaporation and resuspended in H2O (10 mL). The aqueous phase was 
washed with CH2Cl2 (2x 5 mL) and was acidified with 1 N HCl to pH = 3, 
as indicated by pH paper. The aqueous layer was extracted with CH2Cl2 
(4x 10 mL) and the combined organic layers were collected and washed 
with brine (1x 20 mL) and dried over MgSO4. The product was 
concentrated by evaporation and dissolved in water with a minimal 
amount of AcN. After lyophilisation, 14b was obtained as a white powder 
in 74 % yield (107 mg). HPLC: tR = 13.9 min; MS (ES+): 460 [M+H
+, 81Br], 
458 [M+H+, 79Br] (MW: 458.3 g/mol); 1H-NMR (250 MHz, DMSO-d6): δH 
7.27-7.39 (4H, M), 7.03 (2H, d, J= 8.2 Hz), 6.86 (1H, s), 4.09-4.17 (1H, 
m), 3.87 (1H, dd, J= 10.2 Hz, 4.7 Hz), 3.02 (1H, dd, J= 13.1 Hz, 4.9 Hz), 
2.90 (1H, dd, J= 13.0 Hz, 4.6 Hz), 2.28-2.44 (2H, m), 1.34 (9H, s); 13C-
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NMR (63 MHz, DMSO-d6): 171.8, 171.3, 170.2, 155.0, 138.4, 132.1, 
130.2, 118.7, 78.2, 55.1, 51.8, 37.2, 36.1, 28.1. 
Suzuki-Miyaura derivatisation of Asn-Phe dipeptides (14a,b and 12j, 
n): General procedure C 
In a 10 mL MW vial, the dipeptide bromide (0.055 mmol) was dissolved 
together with phenylboronic acid (16.6 mg, 0.136 mmol) and K2CO3 (37.7 
mg, 0.273 mmol or 45.6 mg, 0.330 mmol for 12j, n) in a mixture of H2O 
and iPrOH (1:1, total 2 mL). Formic acid (2 µL, 0.055 mmol) was added 
to the reaction mixture. The catalyst was added in the respective amount 
(5 mol% to 100 mol%, see Table 5). The vial was equipped with a stirring 
bar, closed with a crimp cap and heated to 80°C. Conversion of the 
reaction was monitored by HPLC (215 nm). If satisfactory conversion 
was obtained (only with 5a), the reaction mixture was allowed to cool to 
room temperature, concentrated and redissolved in 5 mL of H2O. 
Preparation of Boc-Asn-Phe(4-phenyl)-OMe (17a) 
Derivatisation of 14a (26 mg, 0.055 mmol) was performed as described 
in general procedure C. The aqueous phase was extracted with CH2Cl2 
(3x 5 mL). The combined organic layers were combined and dried over 
MgSO4. The reaction mixture was concentrated by evaporation and 
resuspended in H2O with a minimal amount of AcN (total 4 mL). The 
product was purified by prep HPLC and obtained as a white powder after 
lyophilisation. Concomitant hydrolysis to 14b was observed by LC/MS 
analysis. Further characterisation indicated that the product was 
hydrolysed. 
Preparation of Boc-Asn-Phe(4-Phenyl)-OH (17b) 
Derivatisation of 14b (25 mg, 0.055 mmol) was performed as described 
in general procedure C using 5a (5 mol%, 2.3 mg, 2,75 µmol). After 
redissolving the crude in H2O, the mixture was acidified with 1N HCl to 
pH= 3, as indicated by pH paper and extracted with CH2Cl2 (3x 5 mL). 
The combined organic layers were dried over MgSO4, concentrated by 
evaporation and redissolved in in H2O with a minimal amount of AcN 
(total 4 mL). The product 17b was purified by prep HPLC and obtained 
as a white powder after lyophilisation in 66 % yield (16.6 mg). HPLC: tR = 
15.0 min; HRMS: [M+Na]+ calculated 478.1949 found 478.1942.  
Preparation of H-Asn-Phe(4-phenyl)-OH (13j) 
Derivatisation of 12j (25 mg, 0.055 mmol), prepared by Fmoc-based 
SPPS (vide supra), was performed as described in general procedure C 
using 5a (5 mol%, 2.3 mg, 2,75 µmol). The obtained aqueous phase was 
washed with CH2Cl2 (1x 5 mL), concentrated by rotary evaporation and 
resuspended in H2O with a minimal amount of AcN (total 4 mL). The 
crude was purified by prep HPLC and lyophilised to obtain 13j as a white 
powder in 32 % yield (7.9 mg). HPLC: tR = 12.2 min; HRMS: [M+H]
+ 
calculated 356.1605 found 356.1632. 
Preparation of H-Gln-Phe(4-phenyl)-OH (13n) 
Derivatisation of 12n (26 mg, 0.055 mmol), prepared by Fmoc-based 
SPPS (vide supra), was performed as described in general procedure C 
using 5a (5 mol%, 2.3 mg, 2,75 µmol). Isolation of 13n was performed as 
described for 13j The crude was purified by prep HPLC and lyophilised to 
obtain 12n as a white powder in 36 % yield (9.3 mg). HPLC: tR = 12.3 
min; HRMS: [M+H]+ calculated 370.1761 found 370.1750. 
 
 
Preparation of Boc-His(BOM)-Phe(4-Br)-OMe (18a) 
To a solution of HCl.H-Phe(4-Br)-OMe (600 mg, 2.04 mmol), Boc-
His(BOM)-OH (918 mg, 2.44 mmol) and HOAt (444 mg, 3.26 mmol) in 
CH2Cl2 (15 mL, SPPS grade) was added DIPEA (1.06 mL, 6.11 mmol). 
The reaction mixture was cooled with a water/ice bath to 0°C and a 
solution of EDC.HCl (625 mg, 3.26 mmol) in CH2Cl2 (5 mL, SPPS grade) 
was added dropwise. After complete addition, the reaction mixture was 
allowed to warm to room temperature and stirred for 16 h. The obtained 
cloudy solution was diluted with CH2Cl2 (25 mL) and filtered over a glass 
frit. The organic phase was washed with saturated NH4Cl (2x 25 mL), aq. 
sat. NaHCO3 (2x 25 mL), water (2x 25 mL) and brine (1x 25 mL). The 
solution was dried over MgSO4 and concentrated by evaporation. After 
drying overnight under high vacuum, 18a was obtained as a white solid in 
99 % yield (1.237 g). HPLC: tR = 15.8 min; MS (ES+): 617 [M+H, 
81Br]+, 
615 [M+H, 79Br]+ (MW= 615.5 g/mol); 1H-NMR (250 MHz, CDCl3): δH 
7.54 (1H, s), 7.28-7.44 (7H, M), 6.85-6.95 (3H, m), 6.75-6.84 (1H, d, J= 
7.6 Hz), 5.23-5.38 (3H, m), 4.73 (1H, dd, J= 13.8 Hz, 6.2 Hz), 4.49 (2H, 
s), 4.33-4.45 (1H, m), 3.68 (3H, s), 2.97-3.14 (3H, m), 2.90 (1H, dd, J= 
14.0 Hz, 6.5 Hz), 1.42 (9H, s); 13C-NMR (63 MHz, CDCl3): 171.1, 170.5, 
155.3, 138.2, 135.8, 134.8, 131.6, 130.9, 128.9, 128.7, 128.4, 128.1, 
127.1, 121.0, 80.4, 73.1, 70.0, 53.8, 53.0, 52.4, 37.2, 28.2, 26.6. 
Preparation of Boc-His(BOM)-Phe(4-Br)-OH (18b) 
Compound 18b (200 mg, 0.373 mmol) was prepared starting from 18a 
according to a similar procedure as described for 13b with LiOH 
monohydrate (78 mg, 1.864 mmol) in THF/H2O (7:1; total 2 mL). After 
lyophilisation, a white powder was obtained in 68 % (133 mg). HPLC: tR 
= 15.1 min; MS (ES+): 603 [M+H, 81Br]+, 601 [M+H, 79Br]+ (MW= 601.5 
g/mol). 1H-NMR (500 MHz, DMSO-d6): δH 8.20 (1H, s), 8.15 (1H, d, J= 
7.5 Hz), 7.41 (2H, d, J= 7.7 Hz), 7.26-7.35 (5H, M), 7.17 (2H, d, J= 7.7 
Hz), 7.01 (1H, d, J= 8.3 Hz), 6.92 (1H, br s), 5.50 (2H, s), 4.46 (3H, m), 
4.28 (1H, m), 2.94-3.08 (2H, M), 2.78-2.93 (2H, M), 1.32 (9H, s); 13C-
NMR (126 MHz, DMSO-d6): 172.3, 170.8, 155.1, 137.5, 137.0, 136.7, 
131.5, 131.0, 128.7, 128.3, 127.7, 127.7, 124.6, 119.7, 78.3, 74.2, 69.7, 
53.1, 53.1, 35.9, 28.1, 26.0.  
Preparation of H-His(BOM)-Phe(4-Br)-OH (18c) 
To a solution of 15c (54 mg, 0.090 mmol) in CH2Cl2 (4 mL) was added 
trifluoroacetic acid (1 mL). The reaction mixture was stirred for 2 hours 
and concentrated by evaporation. After lyophilisation of the product, a 
white powder was obtained in quantitative yield (53.7 mg) as the 
trifluoroacetic acid salt. HPLC: tR = 11.8 min; MS (ES+): 503 [M+H
+, 81Br], 
501 [M+H+, 79Br] (MW= 501.4 g/mol). 1H-NMR (500 MHz, DMSO-d6): δH 
9.19 (1H, s), 8.93 (1H, d, J= 7.5 Hz), 8.42 (2H, br s), 7.50 (1H, s), 7,45 
(2H, d, J= 8.1 Hz), 7.26-7.37 (5H, M), 7.20 (2H, d, J= 8.3 Hz), 5.69 (2H, q, 
J= 10.4 Hz), 4.51-4.59 (3H, M), 4.19 (1H, t, J= 6.4 Hz), 3.29 (1H, dd, J= 
15.7 Hz, 5.7Hz), 3.20 (1H, dd, J= 15.8 Hz, 8.0 Hz), 3.07 (1H, dd, J= 14.0 
Hz, 4.8 Hz), 2.94 (1H, dd, J= 14.0 Hz, 8.4 Hz); 13C-NMR (126 MHz, 
DMSO-d6): 171.9, 167.4, 136.9, 136.5, 136.5, 131.4, 131.1, 128.4, 128.0, 
127.8, 127.2, 121.1, 120.0, 75.8, 70.6, 53.6, 50.8, 35.7, 24.8.  
Preparation of 19a-d 
Histidine-containing dipeptides (19a-b) and tripeptides (19c-d) were 
prepared by standard Fmoc-based SPPS (vide supra). Acylation of the 
C-terminus (19b and 19d) was performed by treating the resin with a 
mixture of acetic anhydride (10 eq) and DIPEA (20 eq) in DMF (3 mL) for 
30 mins. Kaiser ninhydrin test was performed to confirm complete 
acylation of the peptide. Afterwards, the resin was washed consecutively 
with DMF, iPrOH and CH2Cl2 (each 3x 1 min). For final cleavage, the 
resin was treated with a cleavage cocktail (3 mL), consisting of TFA 
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(95 %), H2O (2.5 %) and triethylsilane (2.5 %) for 2 hours. The obtained 
crude peptides were purified by preparative HPLC and obtained as white 
powders after lyophilisation.  
H-His-Phe(4-I)-OH (19a): HPLC: tR = 10.7 min; HRMS: [M+H]
+ calculated 
429.0418 found 429.0400. 
Ac-His-Phe(4-I)-OH (19b): HPLC: tR = 11.6 min; HRMS: [M+H]
+ 
calculated 471.0524 found 471.0520. 
H-Gly-His-Phe(4-I)-OH (19c): HPLC: tR = 10.7 min; HRMS: [M+H]
+ 
calculated 486.0633 found 486.0637. 
Ac-Gly-His-Phe(4-I)-OH (19d): HPLC: tR = 11.5 min; HRMS: [M+H]
+ 
calculated 528.0739 found 528.0738. 
Suzuki-Miyaura derivatisation of His-Phe dipeptides (18a-d, 19a-b) 
and tripeptides (19c-d): General procedure D 
In a 10 mL MW vial, the dipeptide halide (0.02 mmol-0.042 mmol) was 
dissolved together with phenylboronic acid (2.5 eq) and K2CO3 (5-6 eq) in 
a mixture of H2O and iPrOH (1:1, total 2 mL). The catalyst was added in 
the respective amount (5 mol% to 100 mol%, see Table 6). Conversion of 
the reaction was monitored by HPLC (215 nm). The vial was fitted with a 
stirring bar, closed with a crimp cap and heated to 80°C for the 
respective time. Conversion of the reaction was monitored by HPLC (215 
nm). If satisfactory conversion was obtained (only with catalyst 5a), the 
reaction mixture was allowed to cool to room temperature, concentrated 
and redissolved in 5 mL of H2O. 
Preparation of Boc-His(BOM)-Phe(4-phenyl)-OMe (20a) 
Derivatisation of 18a (25 mg, 0.041 mmol) was performed according to 
general procedure D with 5a (5 mol%, 1.7 mg, 2.03 µmol) and K2CO3 
(28.1 mg, 0.203 mmol) for 2 hours. Isolation of the product was similar to 
the purification of 14a, correspondingly, hydrolysis to 20b was observed 
by LC/MS and 1H-NMR analysis, consistent with data found for 20b. 
Preparation of Boc-His(BOM)-Phe(4-phenyl)-OH (20b) 
Derivatisation of 18b (25 mg, 0.042 mmol) was performed according to 
general procedure D with 5a (5 mol%, 1.7 mg, 2.08 µmol) and K2CO3 
(28.7 mg, 0.208 mmol) for 2 hours. The purification was performed as 
described for 14b. After preparative HPLC and lyophilisation, 20b was 
obtained as a pale brown powder in 56 % yield (14.0 mg). HPLC: tR = 
15.9 min; HRMS: [M+H]+ calculated 599.2864 found 599.2869. 
Preparation of H-His(BOM)-Phe(4-phenyl)-OH (20c) 
Derivatisation of 18c (25 mg, 0.042 mmol) was performed according to 
general procedure D with 5a (5 mol%, 1.7 mg, 2.09 µmol) and K2CO3 
(34.6 mg, 0.251 mmol) for 2 hours. Isolation of 20c was performed as 
described for 12j. The product was purified by preparative HPLC and 
obtained as a white powder in 42 % yield (10.4 mg). HPLC: tR = 12.7 
min; HRMS: [M+H]+ calculated 499.2340 found 499.2332.  
Preparation of H-His-Phe(4-phenyl)-OH (20d) 
Derivatisation of 19a (12.5 mg, 0.020 mmol) was performed according to 
general procedure D with phenylboronic acid (6.1 mg, 0.05 mmol), 5a (5 
mol%, 0.8 mg, 1.00 µmol) and K2CO3 (16.6 mg, 0.121 mmol) in 1 mL of a 
mixture of H2O and iPrOH (1:1) for 24 hours. Isolation of 20d was 
performed as described for 12j. After purification by preparative HPLC 
and lyophilisation, the product was obtained as a white powder in 15 % 
yield (1.7 mg). HPLC: tR = 11.9 min; HRMS: [M+H]
+ calculated 379.1765 
found 379.1774. 
Preparation of Ac-His-Phe(4-phenyl)-OH (20e) 
Derivatisation of 19b (12.5 mg, 0.022 mmol) was performed according to 
general procedure D with phenylboronic acid (6.7 mg, 0.055 mmol), 5a (5 
mol%, 0.9 mg, 1.10 µmol) and K2CO3 (15.2 mg, 0.110 mmol) in 1 mL of a 
mixture of H2O and iPrOH (1:1) for 2 hours. Isolation of 20e was 
performed as described for 12j. After purification by preparative HPLC 
and lyophilisation, the product was obtained as a white powder in 19 % 
yield (1.7 mg). HPLC: tR = 12.4 min; HRMS: [M+H]
+ calculated 421.1870 
found 421.1877. 
Preparation of H-Gly-His-Phe(4-phenyl)-OH (20f) 
Derivatisation of 19c (14.0 mg, 0.020 mmol) was performed according to 
general procedure D with phenylboronic acid (6.1 mg, 0.050 mmol), 5a (5 
mol%, 0.8 mg, 1.00 µmol) and K2CO3 (16.6 mg, 0.120 mmol) in 1 mL of a 
mixture of H2O and iPrOH (1:1) for 24 hours. Isolation of 20f was 
performed as described for 12j. After purification by preparative HPLC 
and lyophilisation, the product was obtained as a white powder in 11 % 
yield (1.4 mg). HPLC: tR = 11.5 min; HRMS: [M+H]
+ calculated 436.1979 
found 436.1971. 
Preparation of Ac-Gly-His-Phe(4-phenyl)-OH (20g) 
Derivatisation of 19d (12.5 mg, 0.020 mmol) was performed according to 
general procedure D with phenylboronic acid (6.1 mg, 0.050 mmol), 5a (5 
mol%, 0.8 mg, 1.00 µmol) and K2CO3 (13.8 mg, 0.120 mmol) in 1 mL of a 
mixture of H2O and iPrOH (1:1). Isolation of 20g was performed as 
described for 12j. After purification by preparative HPLC and 
lyophilisation, the product was obtained as a white powder in 29 % yield 
(3.3 mg). HPLC: tR = 11.5 min; HRMS: [M+H]
+ calculated 478.2085 found 
478.2077. 
Synthesis and derivatisation of halogenated phenylalanine 
containing heptapeptide 
Preparation of H-Met-Glu-His-Phe(4-I)-Arg-Trp-Gly-OH (21) 
Heptapide 21 was synthesised following standard Fmoc-based SPPS on 
2-Cl-tritylchloride resin (vide infra) and deprotected with a cleavage 
cocktail (TFA/TES/H2O 95:2.5:2.5) for 3 hours. The resulting crude was 
precipitated in diethylether and purified by preparative HPLC and 
obtained as a white powder after lyophilisation in 19 % yield. (40 mg). 
HPLC: tR = 11.5 min; HRMS: [M+H]
+ calculated 1088.3268 found 
1088.3222. 
Preparation of H-Met-Glu-His-Phe(4-phenyl)-Arg-Trp-Gly-OH (22) 
The heptapide 21 (10.0 mg, 7.3 µmol) was dissolved with phenylboronic 
acid (2.2 mg, 0.018 mmol), K2CO3 (7.0 mg, 0.051 mmol) and 5a (5 mol%, 
0.3 mg, 0.36 µmol) in a mixture of H2O and iPrOH (1:1, total 1 mL) in a 
microwave vial (10 mL). The vial was equipped with a stirring bar and 
sealed with a crimp cap. The mixture was heated to 80°C with an oil bath 
for 2 hours. The mixture was allowed to cool to room temperature and 
concentrated by evaporation. The crude was redissolved in H2O, with a 
minimal amount of AcN, and purified by preparative HPLC to yield 22 as 
a white powder in 18 % yield (1.7 mg). HPLC: tR = 12.4 min; HRMS: 
[M+H]+ calculated 1038.4614 found 1038.4651. 
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Synthesis and derivatisation of C-terminal amide dipeptides 
Preparation of H-AA-Phe(4-Br)-NH2
 (23a-d) 
Dipeptides amides (23a-d) were synthesised on Rink Amide resin, 
following standard Fmoc-based SPPS protocols (vide infra). The first 
amino acid (Fmoc-4-Br-Phe, 3 eq) was coupled together with HCTU (3 
eq) for 60 mins after Fmoc deprotection (20 % 4-methylpiperidine 
solution for 5 minutes and 15 minutes) of the resin. Subsequent 
couplings, deprotection and final cleavage were performed as described 
for 2-Cl-tritylchloride resin. Dipeptides were identified by LC/MS analysis 
and purified by preparative HPLC.  
Entry Peptide 
MW 
(g/mol) 
LC/MS 
[M+H, 
81
Br]
+ 
HPLC  
(min)
[a]
 
1 H-Ser-Phe(4-Br)-NH2 23a 330.2 332 9.9 
2  H-Leu-Phe(4-Br)-NH2 23b 356.3 358 11.3 
3  H-Tyr-Phe(4-Br)- NH2 23c 406.3 408 10.8 
4 H-Ala-Phe(4-Br)- NH2 23d 314.3 316 10.1 
[a] Measured by HPLC (215 nm). 
Preparation of H-AA-Phe(4-I)-NH2 (24a-d) 
Dipeptide amides (24a-d) containing 4-iodophenylalanine were 
synthesised as described for 23a-d with Fmoc-4-I-Phe. After cleavage, 
the peptides were purified by preparative HPLC and obtained as white 
powders.  
H-Ser-Phe(4-I)-NH2 (24a): HPLC: tR = 10.5 min; HRMS: [M+H]
+ 
calculated 378.0309 found 378.0281.  
H-Leu-Phe(4-I)-NH2 (24b): HPLC: tR = 11.6 min; HRMS: [M+H]
+ 
calculated 404.0829 found 404.0786. 
H-Tyr-Phe(4-I)-NH2 (24c): HPLC: tR = 11.1 min; HRMS: [M+H]
+ 
calculated 454.0622 found 454.0618. 
H-Ala-Phe(4-I)-NH2 (24d): HPLC: tR = 10.6 min; HRMS: [M+H]
+ 
calculated 362.0360 found 362.0344.  
Derivatisation of C-terminal amides 23a-d and 24a-d 
The C-terminal amide (0.026 mmol) was dissolved in a 10 mL MW vial 
together with phenylboronic acid (8.0 mg, 0.066 mmol), K2CO3 (18.2 mg, 
0.132 mmol) and 5a (1.1 mg, 1.32 µmol) in a mixture of H2O and iPrOH 
(1:1, total 1 mL). The solution was heated to 80°C for the respective time, 
conversion was determined by HPLC analysis. For the 4-
iodophenylalanine containing dipeptides (24a-d), high conversion was 
observed after 2 hours (6 hours for 24a) and the crudes were purified by 
preparative HPLC yielding the derivatised dipeptides as white powders.  
H-Ser-Phe(4-phenyl)-NH2 (25a) was obtained in 30 % yield (3.3 mg). 
HPLC: tR = 12.1 min; HRMS: [M+H]
+ calculated 328.1656 found 
328.1666. 
H-Leu-Phe(4-phenyl)-NH2 (25b) was obtained in 40 % yield (4.7 mg). 
HPLC: tR = 12.6 min; HRMS: [M+H]
+ calculated 354.2176 found 
354.2205. 
H-Tyr-Phe(4-phenyl)-NH2 (25c) was obtained in 41 % yield (5.3 mg). 
HPLC: tR = 12.2 min; HRMS: [M+H]
+ calculated 404.1969 found 
404.1960. 
H-Ala-Phe(4-phenyl)-NH2 (25d) was obtained in 49 % yield (5.5 mg). 
HPLC: tR = 12.0 min; HRMS: [M+H]
+ calculated 312.1707 found 
312.1720.  
Synthesis and derivatisation of halogenated tryptophan and 
dipeptides containing halogenated tryptophan 
Brominated tryptophans (26a-c) and 7-iodotryptophan (30) were 
synthesised via a biotransformation reaction.[11a] No further purification 
was performed.  
Preparation of Fmoc-5-bromotryptophan  
Compound 26a (500 mg, 1.57 mmol) and Na2CO3 (199 mg, 1.88 mmol) 
were dissolved in H2O (10 mL). To this solution was added a solution of 
Fmoc-OSu (581 mg, 1.72 mmol) in dioxane (10 mL). The suspension 
was stirred overnight at room temperature. The aqueous phase was 
acidified with 1 N HCl to pH= 1, as indicated by pH paper, and extracted 
with CH2Cl2 (4x 30 mL). The combined organic layers were washed with 
1 N HCl (1x 100 mL) and dried over MgSO4. The resultant crude was 
triturated with a mixture of CH2Cl2/hexane (1:1) and the resulting pink 
solid was further purified with silica column chromatography 
(CH2Cl2/MeOH/AcOH 97:2:1) and concentrated to obtain Fmoc-5-
bromotryptophan as a white solid in 71 % yield (561 mg). Rf: 0.19 
(CH2Cl2/MeOH/AcOH 97:2:1). HPLC: tR = 18.9 min; HRMS: [M+Na, 
81Br]+ calculated 529.0560 found 529.0552; 1H-NMR (500 MHz, DMSO-
d6): δH 12.65 (1H, br s), 11.06 (1H, s), 7.87 (2H, d, J= 7.7 Hz), 7.75 (1H, 
d, J= 1.3 Hz), 7.70 (1H, d, J= 8.1 Hz), 7.63 (2H, dd, J= 15.6 Hz, 7.5 Hz), 
7.39 (2H, q, J= 7.1 Hz), 7.22-7.32 (4H, M), 7.17 (1H, dd, J= 8.5 Hz, 1.7 
Hz), 4.14-4.22 (4H, m, 3.15 (2H, dd, J= 14.5 Hz, 4.6 Hz), 2.99 (2H, dd, 
J= 14.5 Hz, 9.8 Hz).  
Spectra were consistent with literature data.[30] 
Dipeptides containing 5-bromotryptophan were prepared according to 
standard Fmoc-based SPPS (vide infra) on 2-Cl-tritylchloride resin with 
Fmoc-5-bromotryptophan. After coupling with the second Fmoc-protected 
amino acid followed Fmoc deprotection and cleavage of the resin, the 
unprotected dipeptides (27a-c) were purified by preparative HPLC and 
lyophilised. 
Entry Peptide 
MW 
(g/mol) 
HRMS 
[M+H, 
81
Br]
+
 
HPLC  
(min)
[a]
 
1 
H-Gly-Trp(5-Br)-OH 
27a 
340.2 
Calc: 342.0272 
Found: 342.0291 
11.3 
2  
H-Phe-Trp(5-Br)-OH 
27b 
430.3 
Calc: 432.0743 
Found: 432.0734 
12.7 
3 
H-Lys-Trp(5-Br)-OH 
27c 
411.3 
Calc: 413.1006 
Found: 413.0999 
10.9 
[a] Measured by HPLC (215 nm). 
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Preparation of 5-phenyltryptophan (28a) 
Compound 26a (HCl-salt, 25 mg, 0.078 mmol) was dissolved with 
phenylboronic acid (23.9 mg, 0.196 mmol) and K2CO3 (54.1 mg, 0.391 
mmol) in 1.6 mL H2O. To this was added 0.01 M 1a solution (0.391 µL, 
3.91 µmol). The reaction mixture was stirred for 2h at 80°C. The reaction 
mixture was cooled to room temperature and concentrated by 
evaporation. The crude was redissolved in H2O with a minimal amount of 
AcN and purified by preparative HPLC. The product was obtained as a 
brown oil after lyophilisation in 54 % yield (16.0 mg). HPLC: tR = 12.4 
min; HRMS: [M+H]+ calculated 281.1285 found 281.1282; 1H-NMR (250 
MHz, DMSO-d6): δH 11.12 (1H, br s), 8.18 (2H, br s), 7.84 (1H, s), 7.62-
7.74 (2H, m), 7.16-7.54 (7H, M), 4.16 (1H, t, J= 5.9 Hz), 3.25-3.33 (2H, m, 
overlap with H2O peak); 
13C-NMR (63 MHz, DMSO-d6): δC 171.0, 142.0, 
135.9, 131.3, 128.7, 127.7, 126.8, 126.2, 125.8, 120.6, 116.6, 111.9, 
107.4, 52.9, 26.1. 
Spectra were consistent with literature data.[5a] 
Preparation of H-Gly-Trp(5-phenyl)-OH (29a) 
Compound 27a (25 mg, 0.066 mmol) was dissolved with phenylboronic 
acid (20.2 mg, 0.166 mmol) and K2CO3 (45.9 mg, 0.332 mmol) in 1.7 mL 
H2O. To this was added 0.01 M 1a solution (332 µL, 3.32 µmol). The 
reaction mixture was stirred for 2h at 80°C. The reaction mixture was 
cooled to room temperature and concentrated by evaporation. The crude 
was redissolved in H2O with a minimal amount of AcN and purified by 
preparative HPLC. After lyophilisation, 29a was obtained as a white 
powder in 33 % yield (9.6 mg). HPLC: tR = 13.8 min; HRMS: [M+H]
+ 
calculated 338.1499 found 338.1504. 
Preparation of H-Phe-Trp(5-phenyl)-OH (29b) 
Compound 29b was prepared starting from 27b (25 mg, 0.054 mmol) 
following the procedure as described for 29a. The product was obtained 
as a white powder after lyophilisation in 24 % yield (5.9 mg). HPLC: tR = 
13.8 min; HRMS: [M+H]+ calculated 428.1969 found 428.1963. 
Preparation of H-Lys-Trp(5-phenyl)-OH (29c) 
Compound 29c was prepared starting from 27c (25 mg, 0.052 mmol) 
following the procedure as described for 29a. The product was obtained 
as a white powder after lyophilisation in 29 % yield (8.9 mg). HPLC: tR = 
11.9 min; HRMS: [M+H]+ calculated 409.2234 found 409.2206.  
Preparation of 6-phenyltryptophan (28b) 
Compound 28b was prepared starting from 26b according to the 
procedure described for 28a. The product was obtained as a white 
powder after preparative HPLC in 38 % yield. (11.2 mg). HPLC: tR = 12.6 
min; HRMS: [M+H]+ calculated 281.1285 found 281.1289; 1H-NMR (500 
MHz, DMSO-d6): δH 11.12 (1H, s), 8.13 (2H, br s), 7.58-7.70 (4H, M), 
7.38-7.49 (3H, M), 7.28-7.35 (2H, M), 7.24-7.27 (1H, m), 4.10-4.18 (1H, 
m), 3.21-3.27 (2H, M, partial overlap with H2O peak); 
13C-NMR (126 MHz, 
DMSO-d6): δC 170.8, 141.6, 136.9, 133.7, 128.8, 128.7, 126.7, 126.5, 
125.8, 118.7, 118.1, 109.5, 106.9, 52.8, 26.2. 
Preparation of 7-phenyltryptophan (28c) 
Compound 28c was prepared starting from 26c according to the 
procedure described for 28a. The product was obtained as a white 
powder after preparative HPLC in 44 % yield. (12.9 mg). HPLC: tR = 12.6 
min; HRMS: [M+H]+ calculated 281.1285 found 281.1279; 1H-NMR (250 
MHz, CD3OD): δH 7.59-7.68 (3H, m), 7.46-7.54 (2H, m), 7.35-7.43 (1H, 
m), 7.24 (1H, s), 7.16-7.19 (2H, m), 4.21 (3H, dd, J= 8.2 Hz, 4.7 Hz), 3.55 
(1H, dd, J= 15.1 Hz, 4.5 Hz) 3.33-3.40, (1H, m); 13C-NMR (126 MHz, 
DMSO-d6): δC 170.6, 138.7, 133.4, 128.9, 128.1, 128.0, 127.2, 125.6, 
125.3, 121.3, 119.2, 117.7, 107.9, 53.0, 26.3. 
Spectra were consistent with literature data.[5a] 
Preparation of 7-vinyltryptophan (31) 
Compound 31 was prepared by dissolving 30 (29 mg, 0.078 mmol), 
potassium vinyltrifluoroborate (26 mg, 0.195 mmol), K2CO3 (54 mg, 0.390 
mmol) and 5a (5 mol%, 3.2 mg, 3.90 µmol) in a mixture of H2O and 
iPrOH (1:1, total 2 mL). The reaction mixture was stirred for 2 hours at 
80°C, allowed to cool to room temperature. The aqueous phase was 
washed with CH2Cl2 (2x 5 mL) and was acidified with 1N HCl to pH = 3, 
as indicated by pH paper. The aqueous layer was extracted with CH2Cl2 
(4x 10 mL) and the combined organic layers were collected and washed 
with brine (1x 20 mL) and dried over MgSO4. The product was 
concentrated by evaporation and dissolved in water with a minimal 
amount of AcN. The crude was purified by preparative HPLC and 
obtained as a white powder after lyophilisation in 51 % yield (13.0 mg). 
HPLC: tR = 11.1 min; HRMS: [M+H]
+ calculated 231.1128 found 
231.1131; 1H-NMR (500 MHz, DMSO-d6): δH 11.19 (1H, s), 8.19 (2H, br 
s), 7.51 (1H, d, J= 7.9 Hz), 7.31 (1H, d, J= 7.5 Hz), 7.25 (1H, d, J= 2.1 
Hz), 7.17 (1H, dd, J= 17.6 Hz, 11.2 Hz), 7.02 (1H, t, J= 7.6 Hz), 5.90 (1H, 
d, J= 17.7 Hz), 5.36 (1H, d, J= 11.1 Hz), 4.09 (1H, t, J= 6.2 Hz), 3.28 (1H, 
dd, J= 15.0 Hz, 5.5 Hz), 3.22 (1H, dd, J= 15.0 Hz, 6.8 Hz); 13C-NMR (126 
MHz, DMSO-d6): 170.8, 134.0, 132.6, 127.9, 125.2, 121.3, 119.0, 118.1, 
118.0, 114.3, 107.4, 52.7, 26.2. 
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methylmorpholine; MW: microwave; pbf: 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-sulfonyl; Pg: protecting group; SAR: 
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phase peptide synthesis; TES: triethylsilane; TFA: trifluoroacetic acid; 
TPPTS: 3,3′,3″-phosphanetriyltris(benzene sulfonic acid). 
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The palladium-catalysed Suzuki-Miyaura derivatisation of (un)protected Phe or Trp, 
and peptide substrates containing halogenated Phe or Trp, is performed via use of 
various water-compatible catalytic systems. Problems associated to the 
unprotected side chains of Asn and His could be circumvented. By mimicking the 
natural aqueous environment of peptides, halogenated moieties are transformed to 
a variety of (hetero)aryl and vinyl subtituents.  
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